Mast cells in human epithelial cancers by Diaconu, Nicolae-Costin
Publications of the University of Eastern Finland
Dissertations in Health Sciences
isbn 978-952-61-0909-1
Publications of the University of Eastern Finland
Dissertations in Health Sciences
d
issertatio
n
s | 133 | N
ico
la
e-C
o
stin
 D
ia
co
n
u
 | M
ast C
ells in H
um
an E
pith
elial C
an
cers
Nicolae-Costin Diaconu
Mast Cells in Human 
Epithelial Cancers
Nicolae-Costin Diaconu
Mast Cells in Human 
Epithelial Cancers
The possible role of MC mediators 
was investigated in SCC and BCC 
carcinomas. Novel information on 
the MC proteinases tryptase and 
chymase in SCC and BCC carcinomas 
is presented and their potential to 
degrade the extracellular matrix is 
discussed. Moreover, the presence 
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TNF-α and histamine leading to the 
spread of SCC. In BCC, MCs express 
TNF-α and CD30 ligand but the lack 
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ABSTRACT 
Mast cells (MCs) release a variety of biologically potent mediators exerting their effects 
either locally or systemically. Many of these are preformed mediators stored in the 
cytoplasmic granules, while others are produced de novo upon MC activation. During the 
last 15 years, human MCs have also been recognized as a source of cytokines and they can 
express a wide range of cell surface molecules. All these molecules may participate in 
carcinoma development through matrix degradation, immunomodulation, angiogenesis or 
tumor cell proliferation. 
In this work, the possible role of MC mediators histamine, heparin, tryptase, chymase, 
TNF-α and other TNF superfamily ligands CD30L and CD40L was investigated in 
squamous (SCC) and/or basal cell (BCC) carcinomas. The expression of these factors in SCC 
and BCC and the possible involvement of mediators in the growth, migration and 
adherence of uterine cervical SCC cells (SiHa and ME-180 cell lines) were studied by using 
histochemical and cell culture techniques. 
The results show that in superficial spreading BCC, the number of tryptase- and chymase-
positive MCs (MCTC cells) is increased, possibly as a consequence of Kit receptor activation 
by the stem cell factor. Even though tryptase was apparently fully active in the BCC lesion, 
chymase was partially inactivated possibly due to action of α1-proteinase inhibitor and α1-
antichymotrypsin localized to mast cells. However, residual chymase activity may still 
cause matrix degradation and other effects in the lesion. In addition, MCs express CD30L 
and TNF-α, but not substantially CD40L, in the BCC lesion. The counterpart receptors of all 
these ligands are present in the lesional epidermis or dermis, but basal buds were negative 
for TNFRI and CD40. In uterine cervical SCC specimens, MCTC cells were detected in 
substantial numbers in the peritumoral stroma, and in vitro especially chymase was capable 
of detaching viable and growing cervical SCC cells from substratum. The amount of 
chymase inhibitor SCCA-2 in cervix cancer cells is low as only weak immunopositivity for 
this antigen was found. In contrast to normal keratinocytes where TNF-α and histamine 
together had a profound growth-inhibitory and cytolytic effect, these mediators did not 
affect markedly the cervical SCC cells. Based on these results, chymase may release viable 
SCC cells from a tumor leading to spreading of SCC. In addition, SCC cells may have lost 
their responsivity to the cytolytic action of TNF-α and histamine, a conclusion based partly 
on the result that SiHa and ME-180 cells and cervix SCC expressed only relatively low 
levels of TNFRI and II. In the BCC lesion, significant changes were found in MCTC cells 
pointing to an intimate involvement in pathogenesis. Decreased chymase activity may not 
be able to degrade TNF-α or cleave the malignant epithelium away, and the lack of CD40L 
in MCs may result in inefficient antitumoral response.  
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1 Introduction 
 
The two most common skin cancer types are basal cell carcinoma (BCC) and squamous cell 
carcinoma (SCC). The incidence of these epithelial and non-melanoma cancer types has 
been increased in the Australian`s white population in an almost epidemic fashion during 
the last 30 years [1]. There is clear epidemiological evidence for a role for UV radiation in 
the development of SCC. The increased incidence of SCC in sunny climates is related to the 
skin type [2]. Basal cell keratinocytes are more tolerant to UV radiation than squamous cells 
because of their stem cell type properties [3]. Intermittent intense sun exposure has been 
considered to be one significant risk factor for BCC [4,5], whereas in the case of SCC, the 
cumulative sun exposure over the lifetime has been incriminated [6,5]. Moreover, a history 
of sunburn in childhood has been described as a significant risk factor for the development 
of BCC [7,8]. 
 
The most common form of cervical cancers of the uterus is SCC which usually arises from 
the metaplastic squamous mucosa in the region of the transformation zone [9]. The risk of 
spreading increases with the depth of the invasion and is less than 1% in the early stages. 
Virtually all cervical SCCs are positive for human papilloma viruses (HPV) and HPV is 
considered to be the main causal factor for the development of cervical cancer [10]. Only a 
limited number of viral types of the family of the HPVs are associated with the etiology of 
SCC. Co-factors that increase the risk among HPV DNA positive women include smoking, 
high parity, the use of oral contraceptives for five or more years and previous exposure to 
other sexually transmitted diseases such as Chlamydia trachomatis and Herpes simplex Virus 
type 2. Human immunodeficiency virus (HIV) increases also the risk for HPV infection, 
HPV DNA persistency and progression of HPV lesions to cervical cancer [11]. 
 
It is well-known that mast cells (MCs) can be found in high numbers in a variety of cancer 
types, especially in the invasion zone [12,13]. Moreover, it is known that MCs are involved 
in cancer invasion directly by their own proteases and indirectly via interactions with other 
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cells [14]. However, little is known of the significance of MCs in epithelial cancer survival, 
growth and invasion. Therefore, the purpose of this study was to investigate MCs and their 
major mediators in BCC and SCC. In the first studies, I and II, the main focus was the 
expression of MC tryptase and chymase as well as TNF superfamily ligands in MCs in 
BCC. In the works III and IV, the possible role and function of MC mediators, including 
histamine, heparin, TNF-α, tryptase and chymase, were studied in uterine cervix SCC. 
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2 Review of the literature 
 
2.1 GENERAL CHARACTERISTICS OF MCS  
 
MCs were first reported by von Recklinghausen and coworkers in 1863 and were identified 
in 1877 by Paul Ehrlich who observed cells with metachromatically staining granules in 
connective tissue stained with an aniline dye and named them "mastzellen", meaning "well-
fed-cells". In particular, during the last decades, MCs have attracted the interest of many 
investigators throughout the world. MCs are large (10 to 15 µm in diameter), ovoid, 
fusiform or triangular mononuclear cells which in their cytoplasm display specific exocrine 
granules enclosed by a single membrane that are particularly avid for metachromatic dyes, 
such as toluidine blue, Giemsa stain, and methylene blue [15]. MCs are derived from 
pluripotent haematopoetic stem cells in bone marrow [16,17], from where undifferentiated 
MC progenitor cells subsequently migrate and circulate in the blood and lymphatic system 
before migrating to their target tissues, especially to various mucosal surfaces and skin 
where they proliferate, differentiate and mature into histologically identifiable MCs 
[18,19,20]. MC migration and differentiation is influenced by several cytokines, such as 
interleukins (IL), IL-3, IL-4, IL-6 and IL-9, and also by nerve growth factor [21,22] and SCF, 
which are secreted locally by stromal cells, such as fibroblasts [23]. These are the only 
cytokines that promote the development of MCs in adult human system [24,17]. MCs, 
ubiquitous cells located in all mammalian connective tissues, are often found in the 
proximity of blood and lymph vessels, in the skin, and in the mucosa of the upper and 
lower respiratory tracts and the gastrointestinal tract [25,26,18], where they play their 
primary defense role as the “sentinel cells” at the interface of the host and environment. 
 
MC subpopulations can be defined on the basis of response specificity [27], tissue migration 
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patterns [25,28] or granule content [28]. Two MC phenotypes, based on their proteinase-
content, tryptase and chymase, have been described in humans: MCT cells contain only 
tryptase as their neutral serine proteinase and MCTC cells have both tryptase and chymase 
and they have primarily been found in the skin and gastrointestinal submucosa. [29,25,30]. 
Chymase-positive and tryptase-negative MCC MCs which are rich in chymase and 
carboxypeptidase have been identified at several body sites, though not markedly in 
normal human skin and, in fact many investigators have failed to detect them [30,31,32,33]. 
In addition, there is experimental evidence from skin organ cultures that the chymase-
positive and tryptase-negative MC may represent an apoptotic MC from which tryptase has 
dissolved away whereas chymase has remained at the site of the dying cell [34,35]. 
However, it has been speculated that there is much more heterogeneity due to the large 
family of proteases that are differentially expressed in MCs. Furthermore, the relative 
amount of tryptase and chymase in MCs may be regulated by cytokines, such as IL-4 [36]. 
Bonini et al. has described MC heterogeneity with respect to Toll-like receptor (TLR) 
expression [37]. 
 
MC stimulation can lead to different responses: exocytosis of secretory granules containing 
proteoglycans and other preformed mediators of immediate hypersensitivity; synthesis and 
secretion of newly-generated mediators, typically produced during IgE-mediated activation 
such as arachidonic acid metabolites, principally leukotriene C4 (LTC4) and prostaglandin 
D2 (PGD2); and synthesis and secretion of cytokines such as tumor necrosis factor-α (TNF-
α), IL-4, IL-5 and IL-6 [38].  
 
MCs are involved in various physiological, immunological and pathological processes, 
particularly in allergic reactions [39], but also in lipoprotein metabolism [40], in the defense 
against parasites and bacteria [41], in gastric acid secretion [42], in autoimmune diseases 
[43], MC disorders (mastocytosis), tissue remodelling and these cells are believed to be 
involved also in tumorigenesis and skin cancer progression [14]. 
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2.1.1 Activation of MCs 
 
An important function of MCs is their ability to release inflammatory mediators by 
degranulation, which involves a complex interaction of signaling molecules. FcεRI 
receptors that bind the Fc portion of immunoglobulin (IgE) antibody with high affinity are 
expressed on the MC surface [44]. Over 70% of the dry weight and 50% of its volume [45] is 
represented by granules, the most specific morphologic feature of MCs [46]. MCs can be 
activated by several diverse stimuli: via IgE-FcεRI binding and antigen recognition, which 
leads to receptor crosslinking and aggregation [47], by tryptic proteases interacting with the 
PAR-2 receptor on skin MCs including the involvement of tryptase [48], by histamine 
releasing factors secreted by neighboring T lymphocytes [49] or macrophages [50], by 
components of the complement system (C3a, C5a) [42], cytokines (e.g., SCF, TNF-α, IFN-γ), 
adenosine, TLR ligands, neuropeptides and hyperosmolality [51]. A novel mechanism for 
degranulation-independent secretion of chemokines from MCs via reverse signaling upon 
CD30L-CD30 interaction has recently been described [52]. However, the mechanisms for 
MC activation in chronic inflammatory diseases have not been completely elucidated (Fig. 
1) [51]. 
 
Figure 1. Mast cell activation after interaction with different ligands, cytokines and T cells (see 
reference [53] for background) 
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MC activation is followed by the process of exocytosis called degranulation when the cytoplasmic 
secretory granule content is rapidly expelled into the extracellular milieu. The exocytosis mechanism 
involves the trafficking of secretory granules to release sites. The granule’s trafficking is controlled 
by a cytoskeletal barrier composed of actin and myosin which undergoes extensive reorganization to 
allow secretory granules to dock and fuse with the plasma membrane to release their soluble granule 
contents [54,55,56]. Finally, the vesicles are recycled by clathrin-mediated endocytosis and the lost 
preformed mediators through rapid onset of de novo synthesis allowing formation of new secretory 
granules [57]. MCs release bioactive molecules including those contained in cytoplasmic granules 
that elicit immediate reactions and those synthesized de novo upon stimulation that exert rather long-
lasting effects [58,59,60,61]. 
 
2.2 MC MEDIATORS 
 
Numerous powerful MC mediators, such as serine proteinases tryptase and chymase, 
histamine, heparin, leukotriene C4, prostaglandin D2, and a wide range of cytokines, 
chemokines and growth factors, enable MC participation in both adaptive and innate 
immune responses [59,60,61]. The release of cytokines in injured skin may have an 
important role in the development of many inflammatory skin disorders [62]. For example, 
in chronic cutaneous inflammatory diseases, MCs exhibit increased levels of IL-4, TNF-α, 
and interferon-gamma immunoreactivity [62,63,64]. Furthermore, MCs are the 
predominant TNF-α positive cell type in psoriasis and atopic dermatitis and the number of 
TNF-α positive MCs was found to be increased in the upper dermis of these skin diseases 
[62]. Human MCs evidently express also many other members of the TNF superfamily, 
such as CD30L, CD40L, 4-1BBL and OX40L [65,66,67]. 
 
2.2.1 Histamine 
Histamine [2-(4-imidazolyl)-ethylamine], a part of imidazoleamine group, is a biogenic 
amine derived from the decarboxylation of the amino acid L-histidine, a reaction catalyzed 
by the enzyme L-histidine decarboxylase (Fig. 2). The major sources of histamine in the 
tissues are MCs [68,69] but there are also other histamine secretors like basophils, 
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macrophages, dendritic cells, T and B lymphocytes [70], endothelial cells, human blood 
monocytes [71], endocrine cells (so-called enterochromaffin-like (ECL) cells) or even cancer 
cells. Histamine is also released from histaminergic neurons where it acts as a 
neurotransmitter. Histamine is stored in the MC secretory granules bound to heparin 
proteoglycan [72] and is secreted after MC degranulation into the extracellular space where 
it rapidly dissociates from heparin. Histamine inactivation involves methylation of the 
imidazole ring catalyzed by histamine-N-methyltransferase or oxidative deamination of the 
primary amino group, catalyzed by diamine oxidase (Fig. 2) [73]. 
 
 
Figure 2. Histamine synthesis and inactivation (modified after Metabolism of histamine - Hubert 
G. Schwelberger) 
Histamine exerts its functions by acting on its specific membrane receptors. The 
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inflammatory wheal and flare response is attributable to the H1 receptor [74]. The H2 
receptor controls typically gastric acid secretion in the gut [75]. The H3 receptor is involved 
in neurotransmitter release in the central nervous system [76]; The H4 receptor, primarily 
expressed in immune cells, has been shown to be involved in chemotaxis and mediator 
release in various types of immune cells, including MCs, eosinophils, dendritic cells and T 
cells [77]. Histamine, a potent vasoactive agent, a constrictor of bronchial smooth muscle 
and the major mediator of the acute inflammatory and immediate hypersensitivity 
responses [78], can affect also chronic inflammation and regulate several essential events in 
the immune response. 
 
Histamine is the best known endogenous agent that evokes itch [79]. In acute urticaria 
histamine is the major mediator released from MC [80]. Even though the essential role of 
histamine in acute dermatological skin diseases is well-known, the role of histamine in the 
epidermis is still largely unknown in chronic skin diseases. 
 
2.2.2 Heparin 
Heparin, a highly sulfated member of the glycosaminoglycan (GAG) family, is a well 
known anticoagulan. It also possesses several non-anticoagulant properties including 
modulation of various proteases [81,82], inhibition of cell growth [83,84] reduction of 
inflammatory responses [85,86] and recently an anti-cancer effect in experimental animal 
models [87], modulations of angiogenesis [88], tumor metastasis [89,90,91,92], and viral 
invasion [93,94,95,96,97,98]. 
 
Heparin is stored, together with histamine, MC proteases and other mediators, in the 
secretory granules of MCs and it is essential for the storage of specific granule proteases in 
MCs [99,100,101]. Histamine is stored in MC granules by electrostatic interactions with the 
highly negatively charged heparin, binding site-specifically to it [102,103], even though 
intragranular histamine is mobile [104]. The details of the interaction between heparin and 
positively charged MC proteases are not known, but it is thought that the interaction is 
utilized by MCs to ensure that only properly folded proteases are targeted to the secretory 
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granule [99]. The release of heparin from these granules in response to injury and its 
subsequent entry into the bloodstream leads to inhibition of blood clotting. 
 
Heparin is expressed in connective-tissue type MCs, where it is biosynthesized as heparin 
proteoglycan [105]. The binding of heparin to MC proteinases and other protein mediators 
can have pronounced effects on the physicochemical and biological functions of the 
mediators. Heparin is essential for keeping tryptase stabile as an enzymatically active 
tetramer [106,107]. Heparin also binds to chymase modulating the detachment of cultured 
keratinocytes [108]. Furthermore, heparin binds efficiently to TNF-α potentiating its 
growth-inhibitory action on cultured keratinocytes [109]. 
Heparin has many properties impacting on carcinogenesis and metastasis including 
mitogenic effect on endothelial cells [110,111], stimulation of the migration of cultured 
capillary endothelial cells [112] and an anticoagulant effect preventing microthrombi 
formation in the new vessels, which helps propagation of metastases. 
 
2.2.3 TNF-α 
TNF-α was isolated as a soluble factor released by lymphocytes and macrophages that 
caused the lysis of a transplanted tumor (sarcoma Meth A) [113]. TNF-α is a 
multifunctional cytokine originally described as a molecule with antitumor properties and 
it is involved in numerous physiological and pathophysiological processes, being the 
prototype of an inflammatory cytokine [114,115]. 
 
TNF-α is mainly produced by macrophages, but also by a diversity of other cells including 
lymphoid cells, MCs, endothelial cells, fibroblasts and neuronal tissue. The MC is the only 
cell type that can store preformed TNF-α in granules and release it rapidly upon activation 
[116]. MCs can also produce large amounts of TNF-α in response to activation. MC TNF-α 
increases vascular permeability [117], stimulates the expression of adhesion molecules 
(ICAM-1 and VCAM-1) on endothelial cells facilitating leukocyte migration to the site of 
inflammation [118,119], provides maturation and migration signals to dendritic cells, 
enhancing the development of immune responses [120,121] and activates macrophages and 
  
 
10
neutrophils for inflammatory mediator production [122,123]. In addition, TNF-α induces 
apoptosis by a cytotoxic effect mediated via TRAIL (TNF related apoptosis-inducing 
ligand) in a variety of tumor cells, but generally not in normal cells [124]. Moreover, MC-
derived TNF also stimulates T-lymphocyte secretion of the gelatinase MMP-9, which 
cleaves type IV collagen and may facilitate the migration of leukocytes between tissue 
compartments [125]. 
 
TNF-α has a large spectrum of bioactivities representing a major proinflammatory 
mediator, with an optional capacity to induce apoptosis. Under certain conditions, TNF-α 
has a distinctive functional duality, being involved in opposite processes such as tissue 
regeneration and destruction [126]. Together with other cytokines, TNF-α is recognized as 
to be a key player in the development of septic shock as high concentrations of TNF induce 
shock-like symptoms. On the other hand, the prolonged exposure to low concentrations of 
TNF can result in the wasting syndrome, cachexia, experienced by tumor patients [127]. 
TNF-α is identified as a key mediator in UV-induced local immunosuppression and its 
levels are increased in UV-exposed skin where it may act by altering Langerhans cell 
morphology and function [128]. Furthermore, large amounts of MC TNF-α are stored and 
released upon activation in UV-induced systemic immunosuppression [129]. 
 
TNF-α has frequently been detected in human cancer biopsies, produced either by 
epithelial or stromal tumour cells. The production of TNF-α has been associated with a 
poor prognosis, loss of hormone responsiveness and asthenia [130,131]. Detected in serum 
of some cancer patients, TNF-α concentrations are elevated in relation to the extent of 
disease. Moreover, TNF-α concentrations are also correlated with serum concentrations of 
IL-8 [132]. 
 
2.2.4 Tryptase  
Tryptase was discovered in 1960 as a trypsin-like activity in MCs [133], and it is the major 
type of proteinase being stored in all human MC granules in a fully active form [134,135]. 
Tryptase, which is enzymatically active in a tetrameric form [81], becomes inactive when 
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the tetramer dissociates into monomers in the extracellular fluid by cleavage or in the 
absence of heparin, resulting in an enzymatically inactive monomeric form of tryptase 
[136]. Since tryptase has four enzymatically active centers in the subunits it has been found 
to be an allosteric enzyme following sigmoidal enzyme kinetics at high salt concentrations 
[137]. The active centers are, however buried in the ring-like tetrameric molecule and they 
are directed towards the central pore [138]. 
 
Four different types of human MC tryptase have been identified. β-Tryptase, the main form 
of tryptase stored in MC granules, is not normally released into the circulation but 
increased levels of β-tryptase can be found in serum during extensive reactions such as 
systemic anaphylaxis. α-Tryptase exhibits to have low activity compared to β-tryptase and 
low levels of α-protryptase have been detected in the circulation even in the absence of MC 
degranulation suggesting that it is released constitutively. The last two types of human 
tryptase, γ- and δ-tryptase, are both expressed in the MC-like cell line (HMC-1) but also in 
airway MCs (γ-tryptase) or colon, lung and heart MCs (δ-tryptase) [135]. 
 
A distinctive attribute of tryptase is its resistance to inhibition by most natural protein 
inhibitors of serine proteinases [139]. According to current concepts, there are no known 
physiological inhibitors to this proteinase. However, serpin B6 has been found to form 
complexes with monomeric beta-tryptase but it is not known whether the tryptase 
monomer is inhibited by this inhibitor [140]. 
 
MC tryptase is believed to exert numerous effects. For example, tryptase up-regulates IL-1 
and IL-8 secretion, mediates accumulation of neutrophils and eosinophils, induces MC 
activation and histamine release, enhances the presence of intercellular adhesion 
molecules/selectins on endothelial cells, produces vascular leakage by fibrinogen 
inactivation, is a moderately potent mitogen for epithelial cells, fibroblasts, and smooth 
muscle cells in vitro leading to increased synthesis and secretion of collagen and it may 
increase the contractility of pulmonary smooth muscle to histamine [141,142,33]. Moreover, 
tryptase is also involved in angiogenesis, degradation of extracellular matrix components 
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by activation of prostromelysin, cleavage of type IV collagen, fibronectin, elastase, and 
proteoglycans, release of matrix-associated growth factors or by indirect activation of 
matrix-degrading metalloproteinases and urinary type plasminogen activator 
[143,144,145,146]. In the skin, tryptase has been found to induce focal dermis-epidermis 
separation at the level of lamina lucida and to degrade fibronectin in the basement 
membrane [147]. Furthermore, it has been suggested that tryptase may be involved in 
matrix destruction in order to make space for migration of tumor cells, and also in 
angiogenesis it is believed to be crucial for tumor survival and growth [143,145,146,148]. In 
addition, tryptase has the capability of diffusing through the matrix and therefore it can 
reach more distant sites after its release from MCs [34,35]. In lesional psoriatic skin, 
tryptase-positive MCs are increased in number throughout the dermis but especially 
beneath the epidermis [149] and the number of tryptase-positive MCs was increased in 
lesional compared with nonlesional skin in AD [62,64] . 
 
2.2.5 Chymase 
Chymase, a neutral serine proteinase with a chymotrypsin-like activity exclusively located 
in the MC granules similarly to tryptase, can be released together with other preformed 
mediators [150]. Chymase is synthesized in an inactive form (pro-chymase) in the MC 
secretory granules where it is stored as a macromolecular complex with heparin 
proteoglycan. Chymase is activated by a thiol proteinase, dipeptidylpeptidase I (DPPI). MC 
chymase is very stable in situ and can be activated immediately after degranulation. 
Chymase hydrolyzes the peptide bonds of proteins, typically after the C-terminal side of an 
amino acid residue with an aromatic structure, such as phenylalanine, tyrosine and 
tryptophan [151]. 
 
Increased levels of chymase inhibitors, α1-AC and α1-PI, have been found in MCs in a 
variety of skin diseases like psoriasis, herpes zoster and blistering skin diseases [149, 
152,153]. Although these inhibitors have been postulated to be a part of the MC secretory 
granules, it is not known whether MCs can synthesize these inhibitors or whether they are 
derived from blood circulation. [154]. Furthermore, secretory leukocyte protease inhibitor 
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(SLPI), which can also inhibit chymase has been shown to be produced by human MC 
[155]. In addition, the light chain of inter-α-trypsin inhibitor that is assumed to be taken up 
by MCs from plasma, has been shown to stain positively in human MCs [156]. Squamous 
cellular carcinoma antigen-2 (SCCA-2), a part of the superfamily of high molecular weight 
serine proteinase inhibitors, inhibits chymotrypsin-like serine proteinases, cathepsin G, and 
MC chymase. In contrast, SCCA-1 is a cross-class inhibitor of papain-like cysteine 
proteinases, such as cathepsins L, S, and K [157]. Moreover, there is a series of chemical 
products able to inhibit serine proteinases. SBTI, a potent inhibitor of trypsin, inhibits both 
chymase and cathepsin G but aprotinin inhibits only cathepsin G and not chymase and, in 
contrast, tryptase is not inhibited by either inhibitor [106,143,34,35]. LBTI (lima bean trypsin 
inhibitor) is a potent inhibitor of chymase but a less potent inhibitor of tryptase [158]. 
 
Similarly to tryptase, chymase also induces degradation of the extracellular matrix and 
basal membrane components, either indirectly by activating MMP-1 pro-collagenase (pro-
MMP-1) [144] or directly by its ability to degrade a variety of extracellular matrix substrates 
[159,160]. Moreover, chymase induces the proliferation of fibroblasts, degrades 
neuropeptides SP and VIP and also acts as an IL-1β convertase, by cleaving inactive 
precursor IL-1β to yield the active molecule. In contrast to tryptase, chymase can stimulate 
indirectly the proliferation of keratinocytes by inducing the formation of angiotensin II. On 
the other hand, it acts similarly to tryptase and inhibits the EGF and α-thrombin induced 
keratinocyte proliferation and subsequently is potentially capable of affecting epidermal 
wound healing [136]. Moreover, chymase also may contribute to the interruption of axon-
reflex-mediated neurogenic inflammation via a negative feedback mechanism of MC-
induced neurogenic activation, since chymase can degrade substance P, CGRP, and other 
neuropeptides [161,162]. Human chymase can induce dermis-epidermis separation in skin 
biopsies at the level of lamina lucida without causing any apparent degradation of laminin 
[163]. Furthermore, chymase can efficiently detach monolayer keratinocytes and 
keratinocyte epithelium from a plastic surface [108].  
 
In the upper dermis of lesional AD chymase apparently loses its activity and the enzyme 
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partially lacks the capability to suppress inflammation, such as degradation of 
neuropeptides and proteins. In addition, the dysregulation of this proteinase can be 
detected already in non-lesional skin of AD [164]. However, the apparent inactivation of 
chymase is not a specific feature of any distinct skin disease, since it has been observed in 
many pathological skin conditions such as psoriasis [149], blistering diseases [165], chronic 
ulcers [166], allergic prick-test reaction [167], and even in skin organ cultures [34,35]. Only 
in irradiation-induced cutaneous fibrosis, any increase in the number of MCs with chymase 
activity has been detected [168]. 
 
2.2.6 IL-8 
IL-8, first purified as a chemotactic factor for neutrophils, has also chemotactic activities for 
T-lymphocytes, basophils and eosinophils [169]. MC tryptase stimulates de novo synthesis 
of IL-8 and may have a role in initiating MC-induced inflammation, though also thrombin, 
a similar protease, can induce the release of this cytokine. Furthermore, TNF-α, a more 
potent stimulus for endothelial IL-8 release than tryptase, has been proposed to be a key 
mediator in granulocyte recruitment at sites of MC activation [170]. MC produced IL-8, a 
major source of this cytokine, promotes rapid accumulation of neutrophils to sites of 
inflammation. Furthermore, it has been speculated that recruited neutrophils may produce 
cytokines such as IL-10, indirectly regulating immune responses [171]. 
 
It has been speculated that IL-8 may be involved in angiogenesis in response to tissue 
injury and may regulate neovascularization and metastasis in tumor. IL-8 has the capability 
of stimulating human keratinocyte migration and proliferation in vitro as keratinocytes 
express both of the IL-8 receptors. Moreover, dermal fibroblasts produce IL-8 even though 
IL-8 mRNA expression by fibroblasts has not been detected at sites of wound healing [172]. 
Additionally, increased number of IL-8-positive MCs in psoriatic and atopic dermatitis 
lesional skin demonstrates that MCs are a marked source of IL-8 in these skin diseases. 
Together with MIP-1α and MIP-1β, IL-8 is capable of recruiting most of the cell types found 
in lesional tissues of these diseases, e.g., accumulation of neutrophils and maturation and 
activation of granulocytes [52,170]. 
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2.2.7 Other MC mediators  
Upon activation, the MC has the capability of releasing a wide array of mediators to fulfill 
its biological functions, including neutral proteases, enzymes other than tryptase and 
chymase (acidic hydrolases, cathepsin G, carboxypeptidase, and metalloproteinases), 
leukotrienes, prostanoids and platelet activating factor (PAF), cytokines, chemokines and 
growth factors. The pattern of produced cytokines depends on the MC type and stimulus 
[173,136]. Thus, MCs synthesize and secrete a diversity of mediators, which are vasoactive 
or regulate inflammation and cellular growth. 
 
Eicosanoids, a group of newly generated mediators of MCs produced from arachidonic 
acid, are rapidly oxidized along either of two pathways – via cyclooxygenase to form PGD2 
and along the lipoxygenase pathway to produce LTC4. PAF, a product of phospholipid 
metabolism in MCs, is also a newly generated mediator. 
 
The MC cytokines and chemokines, preformed and newly synthesized mediators, include 
IL-1β, IL-3, IL-4, IL-5, IL-6, IL-8, IL-9, IL-10, IL-13, IL-16, IL-18, IL-25, TNF-α, granulocyte-
macrophage colony-stimulating factor (GM-CSF), SCF, macrophage chemotactic peptide 
(MCP)-1, 3, 4, regulated on activation of normal T cell-expressed and secreted protein 
(RANTES) and eotaxin [174,150,173,136]. However, the list of cytokines and chemokines 
produced by MCs is continuing to increase. 
 
2.3 NON-MELANOMA SKIN CANCERS 
 
Commonly referred to as non-melanoma skin cancers, BCC and SCC are the most common 
form of cancers in Caucasian populations and the incidence continues to rise due to 
increased exposure to UV-radiation as a result of decreasing ozone levels. About 75% of 
nonmelanoma skin cancers are BCCs, and the majority of the remaining cases are SCCs 
[175]. 
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Many genetic and environmental factors contribute to the pathogenesis of these neoplasms. 
Exposure to UV radiation is considered to be the major causal factor for developing BCC 
and SCC [176,177], but the exposure time is also crucial. UV radiation induces skin cancer 
by DNA mutations or lesions induced by the absorption of UV photons, which may 
produce damage to various immune mechanisms. The damage of the cellular proteins and 
cell membrane carbohydrates and fatty acids may also be a result of UV-induced free 
radicals, which may influence the process of carcinogenesis through altered cellular 
communication, injuries to cell receptor functioning, and alterations in DNA repair systems 
and cell proliferation pathways [178]. 
 
2.3.1 BCC  
BCC, first described by Jacob in 1827, is the most commonly observed neoplasm in the 
Caucasian population. It is usually manifested on sun-exposed areas such as the face, the 
head and neck, and its incidence will surely increase in the future [179]. Even though BCC 
is evidently curable when the diagnosis is made in its early phase, it represents a vast 
financial burden on the health care system [180] and anxiety on an individual level. BCC, 
the most common form of skin cancer in white-skinned races [181,182], is very rare in 
darkly pigmented people [183,184] and its frequency is slightly higher in males. Other risk 
factors include geographic locations with high solar intensity, exposures to ionizing 
radiation [185], ingestion of arsenic alone or in combination with other risk factors [186,187] 
and immunosuppression [188]. Genetic studies show that the formation of sporadic basal 
cell tumors may be induced by the loss-of-function mutations in the tumor-suppressor gene 
patched, or gain-of-function mutations in the smoothened gene [189,190]. 
 
BCC arises from the epidermis and the appendages, which resemble the basal layer of the 
epidermis and is associated with a characteristic stroma [191]. It tends to grow slowly and 
over many years, it invades nearby tissue and spread along the plane of least resistance 
such as periosteum, perichondrium, fascia and tarsal plate [14] which eventually leads to 
ulceration. Even if the tumor has an infiltrating and destructive growth, it does not usually 
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metastasize [7]. Metastasis has been observed in men with large neglected ulcerated 
primary BCC lesions. The aggressive histologic BCC forms like morpheic, basosquamous, 
infiltrating or metatypical showed a higher incidence of metastasis [192]. 
Histopathologically, the tumor appears as proliferating basaloid cells forming cords and 
islands invading into the dermis in most of the cases with a characteristic “palisading” 
arrangement of the peripheral cells and connections between the tumor islands and the 
epidermis. Another characteristic feature of BCC is the retraction of the tumor islands away 
from the adjacent stroma - an artifact which occurs during tissue processing [193]. BCC is 
usually asymptomatic unless ulceration occurs and the carcinoma is characteristically slow 
growing after a period of months to years. It most frequently occurs on sun-exposed (face 
and upper trunk) skin sites and is rare on the palms and soles [194]. 
 
There are five clinical types: nodular, ulcerating, sclerosing (cicatricial), pigmented, and 
superficial. 
Nodular BCC exhibits papule or nodule, translucent or "pearly". In the ulcerating BCC form 
the ulcer is often covered with a crust having a rolled border (rodent ulcer). The sclerosing 
BCC appears as a small patch of morphea or a superficial scar whitish but also with 
peppery pigmentation. In this infiltrating type of BCC there is an excessive amount of 
fibrous stroma. Pigmented BCC may be brown to blue or black and consequently may be 
indistinguishable from superficial spreading or nodular melanoma. It has a smooth, 
glistening surface. Superficial spreading BCC exhibits flat, well-demarcated plaques with a 
rolled edge, which can bleed easily when scratched. It is slow growing, erythematous, with 
minimal induration and located primarily on the trunk e.g. on regions which are most of 
the time covered from the UV exposure. The lesions have a characteristic horizontal growth 
pattern, and often present in multiples [195]. Histologically, superficial spreading BCC 
exhibits characteristically tumour cells budding down from the lower layer of the 
epidermis and palisading around the periphery of the tumour nest [196]. 
 
2.3.2 SCC 
SCC, a malignant tumor arising from epidermal or appendageal keratinocytes or from the 
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squamous mucosal epithelium, carries an overall metastatic rate of 2–6%, with the 
metastasis generally occuring to lymph nodes [197,198,14]. The total number of new cases 
in Finland in 2008 was over 1200, and the annual death rate about 45 [199]. 
 
A history of damage by exogenous carcinogenic agents such as sunlight, ionizing radiation, 
local irritants, or arsenic ingestion is often found in the etiology of SCC. A closer correlation 
between SCCs and chronic cumulative sun exposure than between sun exposure and BCC 
has been observed, in close connection with the latitude gradient [200]. An extremely rare 
but a frecvently reported complication is the development of SCC in chronic burn wounds 
and scars [201]. Mutations in the p53 tumor-suppressor gene have been found in a number 
of SCCs, [202]. An increased risk to develop SCC has been found in patients who have 
received UVB or psoralen plus UVA (PUVA) for the treatment of skin diseases, such as 
psoriasis or mycosis fungoides [203,204,205]. Moreover, a much higher incidence of SCC 
has been reported in immunosuppressed patients [206], e.g., in renal [207] or heart 
transplant recipients [208]. Actinic keratosis is the most common precursor lesion of SCC of 
the skin. The actual percentage of actinic keratosis that transform to invasive squamous cell 
carcinoma varies from 0.1% to 5.0% [209]. Furthermore, SCC in situ also known as Bowen’s 
disease, Erythroplasia of Queyrat or leukoplakia is considered to be another premalignant 
lesion of SCC [195]. 
 
Histopathologically, in the intraepithelial (in situ) carcinoma stage, the limit between 
epidermis and dermis remains sharp throughout the lesion. Subsequently, in the invasive 
stage, the tumor cells are seen to proliferate downwards in cords and single cells into the 
dermis [193]. The tumor may have different degrees of differentiation determined by extent 
of the tumor, with the spindle-cell squamous cells representing the least differentiated form 
[193]. 
 
SCC usually expands faster than BCC. The intraepidermal SCC, the initial lesion, typically 
has a sharply demarcated but irregular outline and appears as a scaly, erythematous plaque 
on sun-exposed areas. Invasive SCC in most of the cases arises from a pre-existing 
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premalignant lesion or from an in situ carcinoma [210]. Regional lymphadenopathy as a 
response to infection of the ulcerated primary lesion or from metastases may be present in 
the invasive form [193]. For didactic reasons, two types can be distinguished: highly 
differentiated SCCs, which practically always show signs of hyperkeratosis of the tumor 
and poorly differentiated SCCs, without any signs of keratinization [195]. 
 
2.4 CERVICAL SQUAMOUS CELL CARCINOMA 
 
Cervical cancer of the uterus, the third most common cancer among women worldwide 
after breast and colorectal cancer and the third most common neoplasm of the female 
genital tract, has long been proposed to have a sexually transmitted etiology. The total 
number of new cases in Finland in 2008 was over 150, and the annual death rate about 55 
[199]. The causal relationship between human papillomavirus (HPV) and cervical neoplasia 
supports an etiologic role for some types of HPV [211]. More than 35 out of over 78 types of 
HPV that have been described are associated with anogenital disease, and 30 or more are 
associated with cancer [212]. Intermediate and high-risk (16, 18, 31, 33, 35, and 45) HPV 
types have been identified in about 77% of high-grade squamous intraepithelial lesions 
(CIN 2 and 3) and in 84% of invasive lesions. HPV 16, the most prevalent HPV type in 
women with cervical neoplasia, being present in up to 50% of high-grade squamous 
intraepithelial lesions and invasive lesions, is the most common HPV type identified in 
cytologically normal women [211,213,214]. Even though a significant role for HPV infection 
in the etiology of cervical neoplasia has been clearly established, other cofactors (sexual and 
reproductive history, smoking, hormonal and dietary factors) are necessary for the 
development and progression of the disease [214]. 
 
Histopathologically, two types of cervix SCC are described: nonkeratinizing carcinoma, 
which is characterized by squamous cells with somewhat hyperchromatic nuclei and a 
moderate amount of cytoplasm growing in discrete nests separated by stroma and 
keratinizing carcinoma characterized by cells with very hyperchromatic nuclei and densely 
  
 
20
eosinophilic cytoplasm growing in irregular invasive nests which in many cases may have 
central “pearls” that contain abundant keratin [215,216]. 
 
2.5 MCS AND THEIR MEDIATORS IN CANCER  
 
As extensively reviewed by many authors [14, 217], the properties of MCs to be present in 
the vicinity of malignant tumors has attracted as much interest and controversy as the 
debate about the functional role of the MC and its wide-ranging and sometimes opposing 
effects in cancer. However, the majority of studies support a secondary role for MCs in 
cancer development and progression (Fig. 3). 
 
 
Figure 3. The accessory roles of MCs in the skin cancer progression and spreading (Modified 
from Ch'ng S et al., 2006 [14]) 
 
MCs accumulate within and around the tumor. Increased MCs density (MCD) has been 
shown in many cancer types including BCC and melanoma [217]. Furthermore, some 
researchers have demonstrated a consistent decrease in MC numbers during tumor 
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progression [218], a decrease which may be due to degranulation of MCs and the 
appearance of phantom cells. However, increased MCD has not always been associated 
with solid tumors and poor prognosis in humans. 
 
MCs accumulate around BCC lesions and may contribute to cancer growth by inducing 
immunosuppression. The MCs present in BCC express VEGF, IL-8 and RANTES [219,14]. A 
higher dermal MC prevalence in non-sunexposed buttock skin has been found in Danish 
patients with a history of sporadic BCC [220]. In clear contrast, there was no significant 
difference in dermal MC prevalence between SCC patients and control subjects. [221]. MCs 
appear to be able to promote tumor development through many different mechanisms: 
immunosuppression, induction of angiogenesis, degradation of the extracellular matrix 
components and promotion of tumor cell mitosis [14]. TNF-α and histamine, which are 
important for the local and systemic effects, respectively, are believed to be the critical MC 
products involved in UV-induced immunosuppression [222]. 
 
Angiogenesis is a crucial mechanism implicated in growth, maintenance, and metastasis of 
solid tumors [217]. Several authors have reported the concept of MC-induced angiogenesis. 
Takeda et al. demonstrated that connective tissue MCs are associated with small vessels 
[223]. Moreover, MCs have been found in many angiogenesis-dependent situations 
including wound healing, hemangioma and neoplasia [217]. In the initiation of 
angiogenesis, degradation of the extracellular matrix components is a critical step and 
tryptase may play a key role in this process by activating metalloproteinases and 
plasminogen activatior. Moreover, in combination with heparin, tryptase may stimulate the 
migration and division of vascular endothelial cells [224]. Additionally, a positive 
correlation between cervical cancer progression and the number of tryptase-positive MCs 
has been demonstrated [217]. IL-8 increases the expression of ICAM-1, which is responsible 
for cell adhesion during angiogenesis [218]. In addition, IL-8 has been found to be inhibited 
by squamous cell carcinoma antigen-2 (SCCA-2), a tumor cell product, and this kind of IL-8 
inhibition has been considered to be involved in the progression of advanced SCC [225]. 
Furthermore, histamine, chymase, bFGF and particularly VEGF have also angiogenic 
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properties and regulate endothelial cell proliferation and function. In addition, VEGF, bFGF 
and platelet-derived growth factor (PDGF) induce MC migration to sites of 
neovascularisation [218,217]. Controversially, some studies have shown that MC-induced 
neoangiogenesis could be associated with greater survival in oral squamous carcinoma or a 
better response to chemotherapy in ovarian cancer. Tryptase-induced fibrosis and 
angiogenesis have been postulated as survival factors in advanced ovarian cancer [225]. 
The proteolytic activity promotes aggressive tumor infiltration to the surrounding tissues 
[218]. Moreover, the higher number of MCs in primary tumors (metastases-free tumors) can 
facilitate the infiltration of lymphatic vessels [218].  
 
Histamine may promote or inhibit tumor cell proliferation by acting through its receptors 
[219]. This has been documented in some in vitro studies suggesting that certain anti-
histaminic compounds promote proliferation of cultured cancer cells. Furthermore, it has 
been shown that a high histamine concentration inhibits primary melanoma cell 
proliferation most likely by acting through H1 receptors, whereas a low concentration had 
proliferatory effect acting via H2 receptors. Thus, H2 receptor antagonist might be 
beneficial by blocking histamine-induced immunosuppression [219]. Moreover, other MC 
mediators including TNF-α, IL-1, IL-6 and interferon-γ have been reported to inhibit 
melanoma cell growth [14]. Heparan sulfate proteoglycans prevented neovascularization 
by blocking the binding of heparin binding growth factors to the cell surface and MC 
chondroitin sulfate may inhibit tumor metastasis by acting as a decoy [219]. MC chymase 
can act as an apoptotic factor on different target cells and chemoattractant for macrophages, 
neutrophils and other inflammatory cells in vivo [225,226,227]. The wide variation of MC 
effects in cancer is still difficult to completely understand their function, although the 
majority of authors do recognise an accessory role for MCs during malignant tumor 
development and progression. 
 
Studies performed in human uterine cervix have revealed that MCT and MCTC are normal 
constituents of the tissue, with the MCT being the predominant phenotype [228]. In both 
benign and malignant lesions of the uterine cervix, these two types of MC have been found 
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and, as is also the case in other types of human tumors [164,229,230], it appears that the 
MCT is the predominant phenotype observed. A constant total number of MC has been 
found during the earlier stages of the carcinogenesis in human uterine cervix (CIN 1–3, CIS) 
but there is an increased number of MCT in invasive carcinomas compared with normal 
tissues [228]. 
 
2.6 TNF LIGAND AND RECEPTOR SUPERFAMILY  
 
All cells in the human body have membrane receptors that induce certain actions in a cell. 
Some stimulate the cell growth, some stimulate cell division, whereas others cause cell 
death. Obviously, those receptors on cancer cells that cause cell death need more attention. 
These receptors are called TNF family receptors. 
 
The TNF ligand and receptor superfamily (Table 1 and 2) has been found to be involved in 
the regulation of innate and adaptive immunity, the induction of apoptosis, but also in the 
reversible formation of secondary lymph organs, the development of sweat glands, teeth 
and hair follicles and regulation of bone homeostasis [231,232]. During the past two 
decades, 19 ligands and 29 receptors that belong to the TNF superfamily have been 
identified. Members of the TNF superfamily mediate hematopoiesis and morphogenesis, 
are believed to be involved in tumorigenesis and tumour metastasis, in transplant rejection, 
septic shock, viral replication, bone resorption, osteoporosis, rheumatoid arthritis and 
diabetes and they act as factors regulating inflammation and autoimmune responses. These 
cytokines or receptor ligands either induce cellular proliferation, survival, differentiation or 
apoptosis having a “double-edged swords” role [233]. 
 
TNF receptor members, with a few exceptions (OPG, TR6 and DcR1), have a single 
transmembrane domain and a cytoplasmic portion without enzymatic activity [231]. All 
members of the TNF receptor family contain at least one copy of the so-called cysteine rich 
domain (CRD) in their extracellular part, a structure of about 40 amino acids stabilized by 
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three cysteine bridges [234]. Usually, one or two CRDs form the contact sites to the 
respective ligands within a single receptor molecule. In some receptor members, e.g. Fas, 
TNFR1, TNFR2, TRAIL-R1 and CD40, the membrane distal CRD serves as a pre-ligand 
binding assembly domain (PLAD) [235,236]. Crosslinking studies with bivalent chemical 
agents have indicated that PLAD-containing receptors occur as homotrimers on the cell 
surface [235,236] and binding of the trimerized ligand might lead to structural changes in 
the PLAD-trimerized receptors rather than to a de novo trimerization per se.  
Most ligands of the TNF superfamily are expressed as soluble proteins (cytokines) or as 
type II transmembrane proteins. One characteristic of the ligands is the formation of non-
covalently linked homotrimers with a unique structure, as indicated by crosslinking studies 
with bivalent chemical agents, but also simply by the fact that these molecules possess 
bioactivity [237,238,239]. Most of the TNF cytokine family members interact with more than 
one receptor of the corresponding superfamily of cognate receptors and vice versa. 
 
2.6.1 CD30 ligand (CD30L) and CD30 receptor 
CD30L and CD30, members of the TNF ligand and receptor superfamily, respectively, 
interact on the cell surfaces and have important immune regulatory functions [240,241]. 
CD30L has been reported to be expressed on a variety of human cell types, including MCs, 
medullary thymic epithelial cells, eosinophils, neutrophils and peripheral blood B cells 
[242]. However, only distinct subsets of B cells from human lymphoid tissue can express 
CD30L constitutively or in response to ex vivo activation [243]. In contrast, in Hodgkin’s 
lymphoma, at least 50% of the MCs display CD30L immunoreactivity, these being the 
predominant CD30L-positive cells. Moreover, the CD30L-CD30 interaction between MCs 
and Hodgkin’s lymphoma may promote the growth of tumor cells, and in this way 
participate in the tumorigenesis process [244]. Increased numbers of CD30L expressing 
MCs have also been found in cutaneous inflammatory diseases, atopic dermatitis and 
psoriasis [52]. 
 
CD30, a marker of anaplastic large cell lymphoma, Hodgkin's disease and other lymphoid 
malignancies [245,246], is also present at inflammatory sites in several human diseases, 
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including atopic dermatitis [247,248], rheumatoid arthritis [249], chronic graft versus host 
disease [250], systemic sclerosis [250,251], seminoma and embryonal carcinoma [252]. It is 
typically expressed on subpopulations of T (Th1 and Th2 cells) and B cells and is observed 
in normal human tissues only on activated blasts in parafollicular areas of lymphoid tissues 
and in the thymic medulla, mainly around the Hassall's corpuscles [246]. Soluble CD30 can 
be detected in the serum of most normal individuals and can be used as a marker of 
tumour extension in Hodgkin's disease and anaplastic large cell lymphoma [253,254,255]. 
Moreover, CD30 was found to be expressed in MC in aggressive Systemic mastocytosis and 
mast cell leukemia [256]. 
 
The CD30L structure, with a C-terminal extracellular domain and a short intracellular N-
terminal domain makes it capable of acting as a receptor and transmitting a downstream 
reverse signal that leads to diverse effects, such as cytokine production. This capacity may 
explain the ability of MCs to produce a wide variety of inflammatory mediators via 
activation of CD30L [52]. It has been reported that CD30L is capable of inducing 
proliferation and IL-6 production by T-cells, IL-8 production and oxidative burst in 
neutrophils [257], impaired immunoglobulin isotype switching in B cells [243], and 
chemokine release in MCs, via CD30L reverse signaling [52]. 
 
2.6.2 CD40 ligand (CD40L) and CD40 receptor 
CD40, identified as a surface marker on bladder carcinomas and on B cells in 1985 [258], has 
a critical role in B cell activation in thymus-dependent humoral responses. Its natural 
ligand, CD40L, a Type II 39-kDa membrane glycoprotein, was first isolated in activated T 
cells in 1992 [259]. A vast array of normal hematopoietic and nonhematopoietic cell types 
has been found to express CD40 and CD40L. Cells with a high proliferative potential, such 
as epithelial and endothelial cells, hematopoietic progenitors, activated monocytes, 
activated B lymphocytes and dendritic cells express CD40 [260]. Moreover, eosinophils, 
CD8+ T cells, fibroblasts [261], cortical, medullary epithelia and interdigiting cells of the 
thymus also express CD40 [262]. CD40 expression has been also found in B-cell 
malignancies, melanomas, and a variety of carcinoma cell types [263,264]. 
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in aggressive Systemic mastocytosis and mast cell leukemia [265]. 
Ta
bl
e 
2.
 E
xa
m
pl
es
 o
f 
C
D
 a
nt
ig
en
s 
in
 t
he
 T
N
F 
fa
m
ily
 r
ec
ep
to
rs
 [
23
1]
 
 CD
 
 
C
el
lu
la
r 
ex
p
re
ss
io
n
 
 
 
M
ol
ec
u
la
r 
  
Fu
n
ct
io
n
s 
 
 
 
 
 
 
 
O
th
er
 
 
 
Fa
m
ily
  
an
ti
g
en
  
 
 
 
 
 
 
w
ei
g
h
t 
 
 
 
 
 
 
 
 
 
 
n
am
es
 
 
 
re
la
ti
on
sh
ip
s 
 
 
 
 
 
 
 
 
(k
D
a)
 
 CD
27
  
M
ed
ul
la
ry
 t
hy
m
oc
yt
es
, 
 
 
55
 
 
 
B
in
ds
 C
D
70
; 
ca
n 
fu
nc
tio
n 
as
 a
 s
tim
ul
at
or
 f
or
 T
 
 
 
 
 
 
TN
F 
re
ce
pt
or
 
 
 
T 
ce
lls
, 
N
K
 c
el
ls
, 
so
m
e 
B
 c
el
ls
  
 
 
 
 
an
d 
B
 c
el
ls
 p
ro
lif
er
at
io
n 
 C
D
30
  
A
ct
iv
at
ed
 T
, 
B
, 
an
d 
N
K
 c
el
ls
, 
 
12
0 
 
 
B
in
ds
 C
D
30
L 
(C
D
15
3)
; 
cr
os
s-
lin
ki
ng
 C
D
30
 
 
 
K
i-
1 
 
 
 
TN
F 
re
ce
pt
or
 
 
m
on
oc
yt
es
  
  
 
 
 
 
 
 
st
im
ul
at
es
 p
ro
lif
er
at
io
n 
of
 B
 a
nd
 T
 c
el
ls
  
 
C
D
40
  
B
 c
el
ls
, 
m
ac
ro
ph
ag
es
, 
de
nd
ri
tic
  
48
 
 
 
B
in
ds
 C
D
15
4 
(C
D
40
L)
; 
re
ce
pt
or
 f
or
 c
o-
st
im
ul
at
or
y 
 
 
 
 
TN
F 
re
ce
pt
or
 
 
 
ce
lls
, 
ba
sa
l e
pi
th
el
ia
l c
el
ls
 
 
 
 
 
si
gn
al
 f
or
 B
 c
el
ls
, 
pr
om
ot
es
 g
ro
w
th
, 
di
ff
er
en
tia
tio
n,
  
 
 
 
 
 
 
 
 
 
 
 
an
d 
is
ot
yp
e 
sw
itc
hi
ng
 o
f 
B
 c
el
ls
, 
an
d 
cy
to
ki
ne
  
 
 
 
 
 
 
 
 
 
 
 
pr
od
uc
tio
n 
by
 m
ac
ro
ph
ag
es
 a
nd
 d
en
dr
iti
c 
ce
lls
 
 C
D
95
  
W
id
e 
va
ri
et
y 
of
 c
el
l l
in
es
, 
in
 v
iv
o 
45
 
 
 
B
in
ds
 T
N
F-
lik
e 
Fa
s 
lig
an
d,
 in
du
ce
s 
ap
op
to
si
s 
 
A
po
-1
, 
Fa
s 
 
 
TN
F 
re
ce
pt
or
 
 
 
di
st
ri
bu
tio
n 
un
ce
rt
ai
n 
 C
D
12
0a
 
H
em
at
op
oi
et
ic
 a
nd
 n
on
- 
 
 
50
–6
0 
 
TN
F 
re
ce
pt
or
, 
bi
nd
s 
bo
th
 T
N
F-
α a
nd
 T
N
F-
β 
 
 
TN
FR
-I
 
 
 
TN
F 
re
ce
pt
or
 
 
 
he
m
at
op
oi
et
ic
 c
el
ls
, 
hi
gh
es
t 
on
  
 
 
ep
ith
el
ia
l c
el
ls
 
 C
D
12
0b
 
H
em
at
op
oi
et
ic
 a
nd
 n
on
- 
 
 
75
–8
5 
 
TN
F 
re
ce
pt
or
, 
bi
nd
s 
bo
th
 T
N
F-
α a
nd
 T
N
F-
β 
 
 
TN
FR
-I
I 
 
 
TN
F 
re
ce
pt
or
 
 
 
he
m
at
op
oi
et
ic
 c
el
ls
, 
hi
gh
es
t 
 
 
 
on
 m
ye
lo
id
 c
el
ls
 
 C
D
13
4 
A
ct
iv
at
ed
 T
 c
el
ls
 
 
 
 
50
 
 
 
M
ay
 a
ct
s 
as
 a
dh
es
io
n 
m
ol
ec
ul
e 
co
st
im
ul
at
or
 
 
O
X
40
  
 
 
TN
F 
re
ce
pt
or
 
 C
D
w
13
7 
T 
an
d 
B
 ly
m
ph
oc
y 
 
 
 
 
 
 
C
o-
st
im
ul
at
or
 o
f 
T-
ce
ll 
pr
ol
ife
ra
tio
n 
 
 
 
IL
A
 (
in
du
ce
d 
by
 
  
TN
F 
re
ce
pt
or
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ly
m
ph
oc
yt
e 
ac
tiv
at
io
n)
, 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4-
1B
B
 
 C
D
15
4 
A
ct
iv
at
ed
 C
D
4 
T 
ce
lls
 
 
 
30
 t
ri
m
er
 
 
Li
ga
nd
 f
or
 C
D
40
, 
in
du
ce
r 
of
 B
 c
el
l p
ro
lif
er
at
io
n 
 
C
D
40
L,
 T
R
A
P,
  
 
TN
F 
re
ce
pt
or
 
 
 
 
 
 
 
 
 
 
 
 
A
nd
 a
ct
iv
at
io
n 
 
 
 
 
 
 
T-
B
A
M
, 
gp
39
 
 
  
 
28
 
Despite its surface receptor, CD40L is expressed transiently on activated leukocytes, MCs, 
eosinophils, and IL-2 activated NK cells [266]. Furthermore, an increased CD40L expression 
in the T cells of patients with myasthenia gravis [267], multiple sclerosis [268] and systemic 
lupus erythematosus [269] has been found and it may produce a proinflammatory signal 
contributing to disease pathogenesis. In rheumatoid arthritis or atheroslerosis, CD40L 
induces and activates metalloproteinases, which function in matrix degradation and tissue 
remodeling [260]. 
 
In 1998, Young et al. postulated that there is an increased tumor susceptibility or 
uncontrolled chronic infection and inflammation due to the loss of CD40L-dependent 
epithelial cell growth regulation [270]. As the majority of oral basal epithelium cells co-
express CD40 and CD40L and in SCC, a loss of CD40L expression and maintained 
expression of CD40 have been observed, it has been proposed that the CD40-CD40L 
interaction could contribute to epithelial tumorigenesis [271]. 
 
2.6.3 TNF receptors I and II 
TNF-α acts via two distinct receptors [272]. Even though the affinity for TNFRI (p55, 
CD120a) is five times lower than that for TNFRII (p75, CD120b) [273], TNFRI is responsible 
for the majority of the biological activities and is expressed on all cell types, while TNFRII 
expression is mainly restricted to immune cells [233]. In contrast to TNFRII, TNFRI is an 
important member of the death receptor family being capable of inducing apoptotic cell 
death due to its death domain (DD) [274]. TNF-α activates via TNFRI both survival and 
proliferation pathways along with apoptotic pathways. The separate pathways are well 
defined, while the survival-apoptosis balance regulation is still poorly understood 
[275,276]. Like other death receptors, TNFRI is able to signal cell death via its cytoplasmic 
death domain in a variety of cell lines. However, in vivo TNF-induced apoptosis seems to 
have only a minor role compared to its overwhelming function in the regulation of 
inflammatory processes.  
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The interaction between TNF-α and its receptors plays a critical role in cellular 
communication during host defense, inflammation and organogenesis but also in many 
other pathological situations, including cancer, which is characterized by an imbalance 
between survival and apoptosis signals. TNFRII is incapable of inducing apoptosis since it 
does not contain a death domain. However, agonistic anti-TNFRII antibodies have clearly 
shown that in some cells exclusive triggering of this receptor is sufficient to induce cell 
death [277,278]. The stimulation of TNFRII induces apoptosis indirectly by induction of 
endogenous membrane TNF, which stimulates the death receptor TNFRI [279]. 
Remarkably, the stimulation of TNFRII produces an enhanced action of the endogenously 
produced membrane-bound TNF on TNFRI. Similarly, the other TNF receptor family 
members lacking a death domain are also able to produce endogenous TNF and to 
indirectly induce cell apoptosis [279].  
 
2.7 SERINE (OR CYSTEINE) PROTEINASE INHIBITOR (SCCA 1 AND SCCA 
2) 
 
Kato and Torigoe (1977, when immunizing a rabbit with a crude extract prepared from 
cervix SCC), described for the first the so called tumor antigen 4 (TA-4). Subsequently it 
was called squamous cellular carcinoma antigen (SCCA). Further analyses revealed that 
SCCA, also called SERPINB3, belongs to the superfamily of high molecular weight serine 
proteinase inhibitors (serpins) [280]. Furthermore, Schneider et al. (1995) found two 
tandemly arrayed genes, the more telomeric and the more centromeric gene, corresponding 
to SCCA-1 and SCCA-2, respectively. 
 
SCCA-1 and SCCA-2 are almost identical members of serpin superfamily and encode for 
proteins with a 98% homology at the nucleotide level and 92% homology at the amino acid 
sequences level. However, significant differences in their reactive site loops suggest that 
they inhibit different classes of proteinases. SCCA-1 is an inhibitor of papain-like cysteine 
proteinases such as cathepsin L, S and K, whereas SCCA-2 inhibits chymotrypsin-like 
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serine proteinases, cathepsin G and MC chymase [281,157]. These findings suggest a role 
for these inhibitors in the control of proteinases, and they may be involved in tumor cell 
motility, invasion, growth and death. 
 
Although clinically used as a serological marker for the management of SCC [282], SCCA is 
also expressed in normal squamous epithelium of the uterine cervix [283]. However, 
significantly increased SCCA-2 mRNA levels, but not of SCCA-1 mRNA levels, have been 
reported in cervical SCC tissue when compared with normal squamous epithelial tissue 
[284]. Moreover, SCCA-1/SCCA-2 mRNA ratios significantly differ between SCC and 
keratinocyte cell line [285]. On the contrary, previous reports revealed by 
immunohistochemical studies using specific antibodies that SCCA-1 and SCCA-2 are 
expressed equally and colocalize in normal and malignant squamous epithelial tissues 
[286]. In order to resolve this discrepancey, further investigation is required on SCCA 
isoform expression in normal and malignant squamous epithelial tissue. 
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3 Aims of the study 
 
The role and significance of MCs in epithelial cancers, or cancers in general, are rather 
obscure. MCs are typically increased in number in the peritumoral stroma but it is not 
known whether MCs promote or inhibit cancer cell growth and invasion. MCs can produce 
and release powerful preformed and newly-synthesized mediators, such as histamine, 
heparin and TNF-α and they also contain serine proteinases tryptase and chymase that are 
stored in the secretory granules of MCs. Upon MC activation by different stimuli, these 
mediators are released and can affect simultaneously the surrounding cells and epithelium. 
Therefore, this thesis work focused on elucidating the possible roles and function of MCs 
and their mediators in human epithelial cancers. Specifically, the aims were: 
 
1. To study whether there are characteristic changes in MC numbers, MC 
types and tryptase and chymase activities in superficial spreading BCC, and 
whether there are changes in different protease inhibitors (α1-PI, α1-AC, 
SCCA-2) known to regulate chymase activity. 
2. To examine whether MCs in superficial spreading BCC express different 
TNF superfamily ligands (TNF-α, CD30L, CD40L) and whether the 
corresponding TNF family receptors are also present in the epidermis 
and/or dermis in this epithelial carcinoma type. 
3. To investigate the influence of histamine and TNF-α on the growth, 
migration and viability of uterine cervical SCC cells in vitro in comparison 
to normal keratinocytes, and to clarify whether TNF-α and its receptors are 
present in uterine cervical SCC. 
4. To determine whether tryptase or chymase is capable of influencing the 
growth, migration or viability of uterine cervical SCC cells in vitro in 
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comparison to normal keratinocytes, and to clarify whether these serine 
proteinases are present in uterine cervical SCC. 
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4 Materials and methods 
 
This chapter covers the materials and methods used in this thesis. A detailed description of 
materials and methods is given in the original publications I-IV. All methods used in this 
study were approved by the Ethics Committee of Kuopio University Hospital, Kuopio, 
Finland. 
 
4.1 TISSUE SAMPLES 
 
Biopsy specimens of the BCC lesion and from the healthy-looking skin at least 2 cm distant 
of the lesion were obtained from patients recruited from the out-patient units of the 
Department of Dermatology, Kuopio University Hospital, Kuopio, Finland or Department 
of Dermatology, Central-Bothnia Central Hospital, Kokkola, Finland (I,II). Two 4-mm 
punch biopsies were taken, one from the peripheral and palpable area of the BCC lesion 
and the other one from the healthy-looking skin at least 2 cm away from the lesion. Two 
biopsy pairs were taken from one patient with several BCCs. The biopsies were taken 
under local anesthesia with lidocaine-adrenaline. After removal, the skin biopsies were 
immediately embedded in optimal cutting temperature medium (OCT) compound (Miles 
Scientific, Naperville, IL) followed by freezing in isopentane cooled with a mixture of 
absolute ethanol and dry ice.  
 
For publications III and IV, formalin-fixed and paraffin-embedded tissue specimens from 
the uterine cervix were obtained and used without identification data from the archives of 
diagnostic specimens of Department of Clinical Pathology, Kuopio University Hospital. 
Biopsy specimens from the uterine cervical SCC and control cervical samples (11 samples) 
with non-specific inflammation had been taken either during the routine Papanicolaou test 
or during surgery and were known to have non-specific abundant inflammatory 
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lymphocyte infiltrates based on the histopathologic examination, without alterations 
attributable to HPV infection. The diagnostic carcinoma biopsies used in the study were 
from 9 patients with uterine cervical SCC verified in the histopathologic examination. 
  
4.2 IMMUNOHISTOCHEMISTRY  
 
Sequential double-staining method was used on cryosections for the localization of CD30L, 
CD40L, TNF-α, IL-8, α1-PI and α1-AC in tryptase-positive MCs (I,II). Briefly, tryptase-
positive MCs were first identified enzyme-histochemically by using Z-Gly-Pro-Arg-MNA 
as the substrate and Fast Garnet GBC as the chromogen. Thereafter, at least 6 adjacent 
photographs per sample lining the epidermis and extending approximately 0.4 mm down 
to the dermis were taken and, thereafter, the red azo dye was dissolved away with 15% 
Tween 20 overnight. In the next step, the same sections were fixed again in cold acetone 
and stained immunohistochemically with the primary antibody, using the Vectastain Elite 
ABC kit for visualization. After re-photographing at exactly the same sites as the previous 
pictures, the positively stained cells were counted by comparing the photographs side by 
side. The results are expressed as the mean percentage of tryptase-positive MCs exhibiting 
immunoreactivity for the primary antibody. Psoriasis sections were used as positive control 
samples since psoriatic lesions have been shown to display the immunoreactivity for these 
antigens (CD30L, CD40L, IL-8, TNF-α) [62]. 
 
Immunostaining of the sections from formalin-fixed and paraffin-embedded specimens was 
performed by the avidin-biotin-peroxidase complex technique using Vectastain ABC Kit 
(Vector Laboratories, Inc., Burlingame, CA) or DAKO Kit (DAKO, A/S, Glostrup, Denmark) 
(III, IV). Samples were deparaffinized, dehydrated and endogenous peroxidase was 
blocked with hydrogen peroxidase. Normal serum was used to block non-specific staining. 
Sections were pre-treated with trypsin (10 mg/ml) or by micro-waving in citrate buffer (pH 
6.0). Primary antibodies (Table 3) were incubated in a humidified atmosphere for 1-3 h at 37 
°C or overnight at 4oC. Diaminobenzidine was used as chromogen and hematoxylin as the 
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counterstain. Controls were performed with mouse immunoglobulins or with rabbit 
preimmune serum. 
 
Table 3. Antibodies used for immunostaining 
 
Antibody      Source     Dilution /pre- 
             treatment 
Mouse monoclonal anti-chymase (I)  Biogenesis Ltd (Poole, UK)  0.1 µg/ml 
 
Mouse monoclonal anti-chymase (IV) Novus Biologicals Inc.   1:200 (this antibody is  
       (Littleton, CO)    suitable for formalin-fixed  
and paraffin-embedded  
specimens) 
 
Rabbit polyclonal anti-α1-PI (I)  Dako (Glostrup, Denmark)  0.28 µg/ml 
 
Rabbit polyclonal anti-α1-AC (I)  Dako (Glostrup, Denmark)  0.61 µg/ml 
 
Mouse monoclonal anti-CD30 (II)  Dako (Glostrup, Denmark)  1:200 
 
Mouse monoclonal anti-CD30L (II)  R&D Systems Europe Ltd  35 µg/ml 
       (Oxon, UK) 
 
Rabbit polyclonal anti-CD40 (II)  R&D Systems Europe Ltd  20 μg/ml 
       (Oxon, UK) 
 
Goat polyclonal anti-CD40L (II)  R&D Systems Europe Ltd  20 μg/ml 
       (Oxon, UK) 
 
Rabbit polyclonal anti-IL-8 (II)   Monosan (Uden, Netherlands)  50 μg/ml 
 
Mouse monoclonal anti-Kit (CD117)  Southern Biotechnology    3 µg/ml 
(II)       Associates (Birmingham, USA) 
 
Mouse monoclonal anti-SCCA-1 (IV)  Santa Cruz Biotechnology  1:50 
       (Santa Cruz, CA, USA) 
 
 Mouse monoclonal anti-SCCA-2 (I,IV) Santa Cruz Biotechnology  1:300 or 1:100 
       (Santa Cruz, CA, USA) 
 
Rabbit polyclonal anti-TNF-α (II)  Harlan Sera-Lab Ltd    50 μg/ml 
       (Loughborough, UK) 
  
Rabbit polyclonal anti-TNF-α (III)  HyCult biotechnology b.v.  25 μg/ml  
(Uden, The Netherlands)   (this antibody is suitable 
for formalin-fixed and 
paraffin-embedded 
specimens) 
 
Rabbit polyclonal anti-tryptase (I,IV)  Harvima I. et al. [287]   0.37-0.4 µg/ml 
 
Goat polyclonal anti-TNFRI (II,III)  R&D Systems Europe Ltd  1:100 or 15 μg/ml 
       (Oxon, UK) 
 
Goat polyclonal anti-TNFRII (II,III)  R&D Systems Europe Ltd  1:200 or 10 μg/ml 
       (Oxon, UK) 
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4.3 CELL CULTURES  
 
Primary human keratinocytes were isolated from human foreskin specimens (III,IV). 
Subcutaneous fat and deep dermis were removed, and the remaining tissue was incubated 
overnight in 0.25% trypsin in solution A (Gibco BRL, Life Technologies). Following the 
incubation, keratinocytes were scraped off from the epidermis with a scalpel and 
suspended in Keratinocyte-SFM medium (GIBCO™-Life Technologies Ltd, Paisley, UK), 
supplemented with 5 ng/ml epidermal growth factor (EGF) and 50 µg/ml bovine pituitary 
extract (BPE) (supplied by the vendor). Keratinocytes were maintained in Keratinocyte-
SFM medium supplemented with EGF and BPE, and passages 1 to 5 were used in the 
experiments. For immunostaining, primary keratinocytes were also cultured on Nunc Lab-
Tek™ chamber slides (plastic, fibronectin or collagen coated) and immunostained with 
antibodies as described for tissue samples. 
 
SiHa and ME180 cells, two cervical SCC cell lines were obtained from the American Type 
Culture Collection (Rockville, MD., USA) (III,IV). SiHa cells were cultured in minimum 
essential medium (MEM) containing 10% FCS, 0.1 mM non-essential amino acids, 1.0 mM 
sodium pyruvate, 1.5 g/L sodium bicarbonate, 100 U/ml penicillin and 100 µg/ml 
streptomycin at 5% CO2 and 37°C. ME-180 cells were cultured in McCoy's 5a medium 
supplemented with 10% FCS. The SCC cells were examined in subcultures 5 to 10 and they 
appeared homogenous in visual inspection. 
 
4.3.1 Apoptosis assays 
The TACS TdT in situ apoptosis detection kit (R&D Systems) was used to determine any 
possible apoptotic changes in SiHa cells and keratinocytes [35] (IV). The cells were cultured 
in 6-well plates until the optimal density was achieved. Subsequently, the medium was 
changed to a basal one and 5 µg/ml rh-chymase was added (Table 4). The detached cells 
were collected and chymase was inactivated with SBTI. In the next step, the viability was 
analyzed with the trypan-blue exclusion method and cytospin preparations were made. In 
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control wells, the cells were briefly incubated with trypsin-EDTA. Afterwards, trypsin was 
inactivated before processing the cells for cytospin preparations. After a short formalin 
fixation, the cytospin preparations were stained using the apoptosis detection kit. The cells 
were counted and the apoptotic index (the ratio of apoptotic cell number to total cell 
number) was calculated. 
 
4.3.2 Cell growth determination by fluorometric DNA assay  
The cell growth was determined using a fluorometric DNA assay and Hoechst 33258 as 
described previously [288,109,289] (III,IV). The cells were seeded in wells of a 24-well plate 
(Nunc, Roskilde, Denmark) and incubated until the optimal cell density was achieved. 
Next, the medium was replaced and various concentrations of modulating agents or 
diluent control were added for 2–3 days. Subsequently, a solution consisting of 8 M urea, 
0.04% sodium dodecyl sulphate, 0.154 M NaCl, and 0.015 M sodium citrate, pH 7.0 was 
added into the wells at 37°C for 1 h to dissolve the DNA of cells. Thereafter, 1.0 µg/ml of 
Hoechst 33258 was added and the fluorescence of the solution was measured using Spectra 
Fluor reader (Q-Lab Pty Ltd, Eagle Farm, Australia).  
4.3.3 Determination of keratinocyte growth and migration  
To determine the growth and migration of normal human keratinocytes under high-
calcium conditions, metallic cylinders were placed (6 mm inner diameter) on the bottom of 
each well of an uncoated 6-well plate (Falcon, Becton Dickinson, Plymouth, UK) [109] (III). 
The wells and cylinders were equilibrated in 5 ml of complete Keratinocyte-SFM® medium 
at 37°C and 5% CO2. Then, about 30,000 keratinocytes, suspended in the same medium, 
were added cautiously into each cylinder. The cells were allowed to adhere onto the plastic 
surface overnight and practically complete confluence of keratinocytes was achieved. Next, 
the metallic cylinders were removed and Keratinocyte-SFM® was changed to 5 ml of 
DMEM, 10% FCS, 100 U/ml penicillin and 100 µg/ml streptomycin, a medium which creates 
high-calcium conditions. Under these conditions, the keratinocytes monolayer begins to 
differentiate and form an epithelium multilayer. After equilibration for 1–2 h, MC 
mediators were added in varying combinations and concentrations. The medium and 
  
 
38
agents were changed every 2–3 days until the epithelium border almost reached the wall of 
the well. Afterward, overnight fixation of the epithelium with 4% formaldehyde followed 
by staining with Mayer's hematoxylin was made. 
4.3.4 Determination of SiHa cell migration and invasion using an in vitro transwell assay 
BD Biocoat™ Matrigel™ Invasion chambers and control chambers (BD Biosciences Europe, 
Erembodegem, Belgium) for 24-well plates were used to study the effect of MC mediators 
on the migration and invasion of SiHa cells (III,IV). In this method, cells were seeded into 
the transwells using incomplete DMEM. The lower well contained complete DMEM. After 
adherence of the cells at 37°C and 5% CO2 for 1 hour, the agents were added in the upper 
transwell chamber. After overnight incubation, the non-migrating and non-invading cells 
were removed from the upper surface of the membrane by "scrubbing". The cells on the 
lower surface of the membrane were stained with hematoxylin and counted under the 
microscope at 200× magnification using an ocular grid [290]. 
4.3.5 Adherence onto fibronectin-coated plastic surface assay 
The method has been described previously [288,109,108] (IV). First, the wells of 24-well 
plates were either uncoated or coated by adding 250 µl of 50 µg/ml plasma-fibronectin in 
D-PBS to the wells overnight. Thereafter, excess fibronectin was washed away and the MC 
mediators were added in varying combinations to the wells overnight. On the following 
day, the solution was washed away with PBS and 1% heat-inactivated BSA was added to 
the wells for 2 h to block non-specific binding. The wells were washed again with D-PBS 
and 1 ml of serum-free DMEM was added to the wells. After 30 min of incubation, about 2 
x 105 SiHa cells in serum-free DMEM were added and the cells were allowed to adhere onto 
the plastic surface for 60 min followed by washing non-adherent cells away with D-PBS 
twice. The SiHa cell adherence was quantitated by measuring the amount of solubilized 
DNA of adherent cells using a fluorometric DNA assay [289]. The analyses were performed 
at least three times using triplicate wells. 
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4.3.6 Determination of cell viability and cytotoxicity 
Cell viability and the cytotoxic effects of different modulating agents was determined with 
the MTT assay as described [109,288] (III). The cells were seeded in wells of a 96-microwell 
plate at a density of about 4,000 cells/well using complete medium. On the next day, the 
medium was replaced with fresh medium. The adhering cells were treated with various 
concentrations of modulating agents for 6–8 h. Then 0.33 mg/ml MTT in incomplete 
Keratinocyte-SFM was added into the wells at 37°C and 5% CO2 for 2 h. Subsequently, the 
MTT solution was removed and the intracellular dye was solubilized by incubating with 
DMSO for 15–20 min. The absorbance of the solution was measured at 550 nm using a 
micro-ELISA reader (SLT-Labinstruments GmbH, Salzburg, Austria). The cultures and 
analyses were made with eight parallel wells and each experiment was performed at least 
four times. 
 
4.3.7 Determination of cell cycle by flow-cytometry 
SiHa cells were seeded in 6-well plates using complete MEM medium (III). The next day, 
the medium was replaced by either complete or incomplete MEM and different modulating 
agents were added for 24 h. Subsequently, the conditioned medium containing possible 
detached cells was collected into a test tube. The attached cells were released by incubating 
in trypsin-EDTA for 10 min. After trypsin inactivation with 10% FCS, the cell suspension 
was combined with the spontaneously detached cells. The final cell suspension was 
centrifuged and washed with D-PBS. For cell fixation, cells were suspended in 0.5 ml of 
cold D-PBS and then were added cautiously, drop by drop, to 5 ml of ice-cold 70% ethanol 
under continuous mixing of the solution as described earlier [109]. After a minimum 
fixation time of 1 day, cells were centrifuged and suspended in D-PBS, treated with 0.15 
mg/ml RNAse at 50°C for 1 h, and incubated in 16 µg/ml propidium iodide at 37°C for 2 h. 
In the final step, the cells were analyzed using a FACScan (BD Biosciences, USA) flow 
cytometer. The experiment was performed three times. 
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4.4 CYTOKINES AND MC MEDIATORS 
 
In order to study the growth modulation and cytotoxicity of different cytokines, 
keratinocytes were cultured on 24-well tissue culture plates. 70-80% confluent cells were 
repeatedly washed with PBS and incubated overnight in Keratinocyte-SFM medium with 
supplements. Subsequently, keratinocytes were treated with different cytokines or growth 
factors for 24 h (Table 4). All treatments were conducted in Keratinocyte-SFM medium with 
or without supplements. After 24 h, total DNA was extracted from the cells with untreated 
cells being used as a control. 
 
Table 4. MC mediators used in the study 
 
Cytokine or MC mediator     Source 
Heparin sodium salt      Fluka BioChemica (Buchs, Germany) 
 
Histamine diphosphate monohydrate    Fluka BioChemica (Buchs, Germany) 
 
Rh-TNF-α        R&D Systems Europe Ltd (Oxon, UK) 
 
Rh-chymase       R&D Systems Europe Ltd (Oxon, UK) 
 
Tryptase-chymase preparation     Prepared in our laboratory [108]   
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5 Results 
 
5.1 TRYPTASE- AND CHYMASE-POSITIVE MCS ARE INCREASED IN 
NUMBER AND ARE ASSOCIATED WITH PROTEASE INHIBITORS IN BCC (I) 
  
BCC lesions showed more MCs than healthy-looking skin (I, Fig. 1). In the BCC lesions, the 
numbers of MCs with tryptase activity and those with chymase immunoreactivity were 
significantly increased by 2.2-2.3-fold when compared to the situation in the healthy-
looking skin samples. However, the ratio of cells with chymase activity to those with 
chymase immunoreactivity was significantly decreased in BCC lesion (I, Table 1), possibly 
due to chymase inhibitory effects of α1-PI, α1-AC or SCCA-2. 
 
To clarify further whether tryptase and chymase are inactivated in the BCC lesion, the 
sequential double-staining method for tryptase and immunoreactivity for chymase 
inhibitors was utilized. The results showed that only occasional tryptase-immunopositive 
cells (about 1%) did not display tryptase enzyme activity, and the expression of chymase 
inhibitors α1-AC and α1-PI was significantly increased (I, Table 1). SCCA-2 
immunoreactivity was strongly increased in the malignant BCC epithelium, mostly in the 
suprabasal layers. Interestingly, the entire BCC epithelium was stained except for the basal 
part, which appeared to be either unstained or weakly stained (I, Fig. 3). Large basal buds 
attached to the BCC epithelium were negative for SCCA-2 (I, Fig. 3). 
 
5.2 BCC LESIONS DISPLAY INCREASED CD30L/CD153 AND TNF-α 
EXPRESSING MCS (II) 
 
The upper dermis of BCC lesions display over twofold higher amounts of tryptase-positive 
MCs, many of them in close apposition to the BCC epithelium. Moreover, a significantly 
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increased number of cells positive for Kit was found, the latter being an important growth 
and survival receptor on MCs (II, Table 1).  
 
A statistically significant increase in the percentage of MCs displaying CD30L in the BCC 
lesions is evidence that CD30L is up-regulated in these MCs. In addition, MCs in BCC 
lesions were one of the predominant cell types exhibiting CD30L immunoreactivity (II, Fig. 
1). Furthermore, the counterpart, CD30 immunopositive cells, was found to be increased in 
number in the upper dermis of BCC lesion (II, Table 1; Fig. 2). In contrast, the epidermis of 
the healthy-looking skin and the BCC epithelial compartment showed only occasional 
scattered CD30-positive cells (II, Fig. 2). 
 
MCs were practically devoid of CD40L immunopositivity and only rare occasional MCs 
displayed slight CD40L staining in the BCC lesion (II, Fig. 5). The counterpart, CD40 
positive cells, showed significantly higher scores in the upper dermis of the BCC lesion 
compared to the situation in healthy-looking skin (3 ± 0 versus 1.8 ± 0.5, p = 0.00012, 
respectively). The basal layer of the epidermis of the healthy-looking skin and BCC 
epithelium displayed CD40 immunoreactivity but not the upper layers (II, Fig. 6). Many 
larger basal buds were mostly negative for CD40 in the BCC lesion even in the basal layers 
(II, Fig. 6). 
 
An increase, although statistically non-significant, in the percentage of TNF-α-positive MCs 
in the BCC lesions was observed when compared with the healthy-looking skin (36.7% 
versus 27.0%) (II, Table 2). However, the increased number TNF-α-positive MCs in the BCC 
lesion appeared to be a result of the increased number of tryptase-positive MCs in the 
upper dermis. In addition, MCs appeared to be the predominant cell type displaying TNF-
α immunopositivity in the BCC lesion (II, Fig. 3). The counterpart TNFRI- and TNFRII-
positive cells were found to be significantly increased in number in the BCC lesional dermis 
when they were semiquantitatively analyzed (II, Table 2). Both TNFRs were detected 
similarly in the viable healthy epidermis and BCC epithelium (II, Fig. 4) though larger basal 
buds in 5 cases showed no TNFRI. 
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The proinflammatory cytokine IL-8 has recently been described to be produced by MCs in 
psoriasis and atopic dermatitis [52]. Using a double-staining method for IL-8 we found a 
significantly higher percentage of IL-8-positive MCs in the upper dermis of the BCC lesions 
compared to healthy-looking skin (5.5 ± 6.5 versus 1.1 ± 1.2%, P = 0.037, respectively), 
although the percentage values were generally low. 
 
5.3 TNF-α AND HISTAMINE DO NOT INFLUENCE THE GROWTH OF 
SQUAMOUS CARCINOMA CELLS FROM UTERINE CERVIX WHEREAS 
NORMAL KERATINOCYTES UNDERGO CYTOLYSIS (III) 
 
Histamine alone did not evoke any stimulatory effect on SiHa or ME-180 cell growth after 
cultivation in complete or incomplete medium (III, Fig. 1). In incomplete medium, TNF-α 
alone significantly inhibited the growth of SiHa or ME-180 cells. The combination of 
histamine (0.1 and 1 mM) and TNF-α (10 and 50 ng/ml) did not produce any additional 
inhibitory effect over that of TNF-α alone on SiHa or ME-180 cell growth. In contrast, the 
growth of normal keratinocytes was significantly inhibited by histamine (1 mM) or TNF-α 
(10 or 50 ng/ml) and, furthermore, the inhibitory effect was found to be cumulative in both 
complete and incomplete Keratinocyte-SFM medium (III, Fig. 3). 
 
The combination of 0.1 or 1 mM histamine and 10 or 50 ng/ml TNF-α produced significant 
cytotoxic effects on normal keratinocytes (III, Fig. 5a). In contrast, neither histamine nor 
TNF-α, nor both in combination, could induce any marked cytotoxic effect on SiHa or ME-
180 cells (III, Fig. 5b, c). After treatment with emetine, a protein synthesis inhibitor, which 
has the capacity to render SiHa cells susceptible to the cytotoxic effects of TNF-α [291], the 
combination of histamine and TNF-α did not cause any increase in cytotoxicity on SiHa 
cells when compared to TNF-α alone (III, Fig. 6). In addition, neither TNF-α at 10 and 50 
ng/ml, histamine at 0.1 and 1 mM nor their combination of both could induce apoptotic 
events above the control level (3.9% in incomplete and 0.9% in complete medium), although 
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TNF-α alone slightly induced cell cycle arrest at G0/G1 phase especially in incomplete 
medium. 
 
Histamine alone (0.1 or 1 mM) was unable to modulate SiHa cell migration. In contrast, 
TNF-α produced a significant increase in cell migration. Combination of histamine (0.1 or 1 
mM) and TNF-α (10 or 50 ng/ml) could not induce any additional effect over the one 
achieved by TNF-α alone (III, Fig. 8). Furthermore, neither histamine nor TNF-α alone or in 
combination, using the same mediator concentrations as in the migration assay, induced 
any significant changes on SiHa cell invasion by using the Matrigel transwell assay.  
 
To explain the TNF-α effects on keratinocytes and cancer cells, the presence of the 
counterpart receptors, TNFRI and TNFRII, was confirmed in these cells using 
immunostaining techniques. Overall, 52% and 36% of the keratinocytes were positive for 
TNFRI and TNFRII (III, Fig. 9), respectively. In clear contrast, SiHa and also ME-180 cells 
displayed only weak immunopositivity, having far less intensity for both TNFRs than 
keratinocytes.  
 
Immunostaining was used to evaluate the presence of TNF-α and its receptors in cervix 
carcinoma samples. Clear immunopositivity for TNF-α in cervix carcinoma samples was 
found in seven out of eight cases in the tumor cells and peritumoral stroma (III, Fig. 11b). 
Control samples showed clear immunopositivity for TNF-α inside the epithelium (III, Fig. 
11a). In addition, control samples displayed immunopositivity with TNFRI localized in the 
basal layers of epidermis, whereas one sample showed positivity in the upper keratinocytes 
(III, Table 2). Half of the carcinoma samples had lost their positivity for TNFRI. In contrast, 
TNFRII showed positivity in the upper layers of epidermis in all control samples, whereas 
tumor cells were considered to be negative in two cases. Interestingly, two samples were 
negative for both TNFRs (III, Fig. 12). 
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5.4 MC CHYMASE IS PRESENT IN UTERINE CERVICAL CARCINOMA AND IS 
CAPABLE OF DETACHING VIABLE AND GROWING CERVICAL SQUAMOUS 
CARCINOMA CELLS FROM SUBSTRATUM (IV) 
 
The numbers of chymase-immunopositive cells were found to be similar in the upper 
subepithelial stroma of control tissue and in the peritumoral stroma of SCC (IV, Fig.1a) 
(69±21 versus 62±58 cells/mm2, respectively). Furthermore, similar numbers of tryptase-
positive cells were found in the peritumoral stroma of SCC (81±60 cells/mm2) and in 
controls (99±54 cells/mm2) (IV, Fig. 1b). Interestingly, the ratio of the number of chymase-
positive cells to that of tryptase-positive cells was similar in all areas – 75±29% in the 
peritumoral stroma, 79±18% in the normal-looking tissue of SCC samples, and 74±22% in 
control samples. Tumor cells and the epithelium of control samples did not show 
immunopositivity for tryptase and chymase. 
 
Immunohistochemical staining for SCC antigens revealed only weak immunopositivity for 
SCCA-2 in 4 cervical SCC specimens and clear immunopositivity in only one specimen (IV, 
Fig. 2a, Table 1). However, no SCCA-1 staining was detected in any of the SCC specimens. 
Instead, immunopositivity for SCCA-1 in the squamous layer of the epithelium was 
detected in all control specimens (IV, Fig. 2b, Table 1), though these specimens did not 
express SCCA-2. 
 
The tryptase-chymase preparation, in the absence of heparin, caused effective detachment 
of SiHa cells from the plastic surface (IV, Fig. 3a) when the cells were cultivated in 
incomplete medium. Furthermore, SBTI, an inhibitor of both chymase and cathepsin G, 
completely prevented the changes induced by the tryptase-chymase preparation whereas 
aprotinin, which inhibits only cathepsin G [108] had no effect. In addition, neither 
histamine nor heparin was able to affect the cell detachment in the presence of tryptase-
chymase preparation. Interestingly, over 86% of the SiHa cells detached by the tryptase-
chymase preparation were found to be viable by the trypan-blue exclusion method. This 
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finding was confirmed when detached cells were transferred to another 6-well plate and 
found to continue their growth in an apparently normal fashion. 
 
In clear contrast to SCC cells, prolonged treatment with rh-chymase reduced the cell 
viability and induced apoptosis in detached normal keratinocytes. The viability of the cells 
was estimated using two different methods: trypan-blue exclusion and cytospin 
preparations stained with Apoptosis detection kit (IV, Fig. 8). 
 
The detachment and/or reduced adherence of SiHa cells onto substratum by tryptase 
and/or chymase was a result of matrix protein cleavage, since SiHa cell adherence onto the 
pretreated fibronectin-coated plastic surface was inhibited by overnight treatment with the 
tryptase-chymase preparation. Moreover, DFP, a serine proteinase inhibitor, when 
combined with the enzyme preparation prevented the cell detachment. In contrast, TLCK, 
an effective inhibitor of tryptase [108] had no marked effect on cell adherence. In addition, 
aprotinin did not prevent the effect of the tryptase-chymase preparation, which effectively 
decreased the cell adherence. In contrast, SBTI markedly inhibited the effects of the 
tryptase-chymase preparation, indicating that it was chymase, which was responsible for 
the decreased adherence of SiHa cells to fibronectin (IV, Fig. 5). Furthermore, rh-chymase 
degraded fibronectin in a dose-dependent manner as confirmed using the SDS-PAGE assay 
(IV, Fig 6). 
 
In addition to the tryptase-chymase preparation, rh-chymase was capable of inhibiting the 
cell growth probably due to its ability to detach viable cells from the plastic surface. The rh-
chymase effect was a result of its catalytic properties since SBTI completely prevented the 
changes induced by rh-chymase, though SBTI on its own had no effect on cell detachment 
(IV, Fig. 7). Also, it was found that rh-chymase could inhibit SiHa cell migration in a dose-
dependent manner, probably owing to it´s capability of detaching cells, and SBTI 
completely prevented this effect (IV, Fig. 9). 
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To find out whether SiHa cells are capable of inhibiting chymase, the chymotryptic activity 
of SiHa cells was first studied by sonicating a cell suspension in an ice bath. The result 
showed that SiHa cell sonicate itself contained only weak, if any, chymotryptic activity. 
Next it was found that the SiHa cell sonicate did not markedly inhibit rh-chymase activity 
(IV, Fig. 10). Since SCCA-2 is a well known chymase inhibitor [280], it was studied whether 
the SiHa cells contained any immunoreactivity for SCCA. Hence, SiHa cells cultured in 
chamber slides were immunocytochemically stained for SCCA-1 and -2 using monoclonal 
antibodies (IV). Only weak, if any, expression of SCC antigens in SiHa cells was found. 
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6 Discussion 
 
MSc are usually increased in number in different cutaneous malignancies, and MCs are 
thought to contribute to skin carcinogenesis by immunomodulation, induction of 
angiogenesis, degradation of the extracellular matrix components, and promotion of 
mitogenesis. The development of skin carcinomas requires malignant transformation and 
compromised immune system [53]. UV radiation is the major causative factor for skin 
carcinogenesis and MCs evidently have an essential role in UV-induced 
immunosuppression using different mechanisms [5,129,181,202,53]. The recruitment of 
immunomodulatory or immunosuppressive MCs to the skin tumor may be due to 
carcinoma cell-derived SCF and Kit receptor on MCs [292] There is recent experimental 
evidence to support this mechanism [293].  
 
In addition to the regulatory role, MCs are often considered to be proinflammatory cells in 
chronic tissue inflammation. This function of MCs can be in line with the concept that 
cancer development is often accompanied by an inflammatory response and peritumoral 
inflammatory cell infiltration. However, sufficient immunosuppression may be required to 
prevent the harmful damages to the tumor by inhibiting the excessive inflammation 
[293,294]. 
 
This background should be kept in mind when interpreting the results of the study. It is not 
known in which situation MCs act as proinflammatory cells and in which conditions they 
behave like immunosuppressive cells [53].  
 
6.1 PARTIAL INACTIVATION OF CHYMASE AND INCREASE IN PROTEASE 
INHIBITORS IN BCC 
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Previously, tryptase-positive MCs have been found in the adjacent stroma of the BCC lesion 
[295] and other types of human cancers, such as breast cancer, oral SCC and malignant 
melanoma [13,296,297]. This suggests that tryptase may be involved in matrix degradation, 
an important factor for tumor survival and growth [143,145,146,148]. In our study, the 
number of MCs with tryptase activity was increased by 2.2-fold in the BCC lesion. One 
explanation for the accumulation of mast cells in the upper dermis close to the malignant 
epithelium in BCC is the expression of α3-integrin on mast cells and thereby these cells can 
bind to laminins LM-332 and LM-511 in the basement membrane [298]. 
 
 
MCs in the BCC lesion are probably in an activated form leading to increased degranulation 
and exposure of serine proteinases tryptase and chymase to protease inhibitors at 
physiological pH [299]. However, only about 1% of the tryptase-immunopositive cells in 
the BCC lesions did not display any tryptase activity. These rare MCs with inactive tryptase 
may be a result induced by the action of serpin B6 inhibitor or a result of a technical artifact 
due to section processing [140]. Similar situation has been found in herpes zoster lesions 
where only occasional tryptase-immunopositive cells were devoid of enzyme activity [153]. 
Consequently, tryptase is virtually in a fully active form, able to affect surrounding cells 
and matrix components in the BCC lesion, a conclusion supported by the fact that there are 
no known endogenous inhibitors for tetrameric tryptase. Independent of these 
considerations, agents which dissociate tetrameric tryptase from heparin proteoglycan can 
inactivate this enzyme since the tetrameric form dissociates into inactive monomers [300]. 
 
In contrast to tryptase-heparin proteoglycan complexes, the chymase-heparin proteoglycan 
complexes are larger in size and tend to remain at the site of MC degranulation [34,35]. The 
soluble form of chymase is effectively inactivated by α1-AC even though in the acidic MC 
granules tightly packed chymase appears to be relatively insensitive to this protease 
inhibitor [34]. Furthermore, chymase-immunopositive cell number was significantly 
increased by 2.3-fold in the BCC lesion, suggesting a high number of the MCTC type of MCs. 
In contrast, a 1.6-fold increase in number of MCs displaying chymase enzyme activity and a 
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significantly decreased ratio of cells with chymase activity to those with chymase-
immunopositivity are an evidence that chymase is partially inactivated in the BCC lesion. 
 
Several different protease inhibitors are either synthesized in human MCs and/or taken up 
from the extracellular environment [152,155,156]. In our study, the significant 1.7-fold 
increase in the percentage of MCs showing α1-PI or α1-AC immunoreactivity in the BCC 
lesion could well explain the apparent inactivation of chymase, even though SLPI [155] 
could be another candidate for chymase inhibition. A similar inactivation of chymase to 
that detected in the BCC lesion has been observed in other pathological skin conditions, 
such as blistering diseases [165], psoriasis [149], chronic ulcers [166], allergic prick-test 
reaction [167], and even in skin organ cultures [34,35]. Therefore. the findings of this study 
are not specific to BCC, and partial inactivation of chymase may just reflect chronic 
inflammation in this carcinoma type. 
 
Chymase has potentially destructive effects to the epidermis and epithelium producing 
epithelium detachment [163,108]. Therefore, the enzyme has to be in tight control in normal 
skin to prevent epidermis-dermis separation every time mast cells activate and degranulate, 
e.g., in urticarial wheal. Chymase is capable of degrading and inactivating it´s inhibitors α1-
PI and α1-AC [301]. In the chronic inflammation of BCC lesion, it is possible that an 
equilibrium between chymase inactivation and degradation of its inhibitors may have been 
reached [301]. However, chymase was not completely inactivated and the residual chymase 
activity may still be sufficiently high to have a marked influence on the stromal cells, 
basement membrane structures and BCC cells. It may even be possible that a fully active 
chymase is needed for removing the malignant epithelium away, but chymase fails in this 
task. 
 
SCCA-2, a non-specific disease marker for squamous cell cancer, has also the capacity to act 
as a chymase inhibitor. In this work, SCCA-2 was increasingly expressed in the areas of the 
malignant BCC epithelium but larger basal buds, often surrounded by MCs, were negative 
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for this antigen. Thus, even though a strong expression of SCCA-2 was found in the BCC 
lesion, it appears not to be as crucial chymase inhibitor as α1-PI or α1-AC. 
 
6.2 TNF-α AND CD30L BUT NOT CD40L IMMUNOPOSITIVE MCS IN BCC 
LESION 
 
Previously, an increased number of MCs in upper dermis of psoriasis and BCC lesion has 
been reported. Moreover, in psoriasis, MCs displayed immunoreactivity for TNF-α and 
CD30L [62,63,52,295,302,303]. However, only limited data is available on the CD40L 
expression in cutaneous MCs. In this study, the increased number of MCs in BCC lesion 
was confirmed and MCs appeared to be one predominant TNF-α-positive cell type in BCC 
lesion. However, the increased number of TNF-α-positive MCs in the upper dermis and the 
percentage of TNF-α-positive MCs in the healthy-looking skin of BCC patients were similar 
to those found previously in atopic dermatitis and psoriasis [62]. Since chymase can 
degrade TNF-α to some extent [304] and the enzyme is partially inactivated in the BCC 
lesion (I), it is possible that inactivation of chymase allows more effective actions of MC 
TNF-α. 
 
Markedly increased scores of TNFRI- and TNFRII-positive cells were found in the upper 
dermis of the BCC lesion. These receptors may have the capability of regulating the tumor 
cell death and inflammation just beneath the BCC epithelium when receptor-positive cells 
are stimulated by soluble TNF-α released from MCs [305]. The staining pattern for TNFRI 
and TNFRII in BCC resembled the staining in psoriatic epidermis showing perinuclear 
accentuation but, in contrast to the positively stained parakeratotic area of the psoriatic 
epidermis, the uppermost stratified area in the BCC epithelium was negative. Thus, based 
on these histochemical results, MC TNF-α may interact directly with TNFR-positive cells in 
the dermis and BCC epithelium. However, TNF-α may be captured before it reaches its 
target cells by the serum levels of TNFRI, but not that of TNFRII, and as a result the 
antitumoral response is impaired [306]. 
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The specific biological effects of the CD30L-CD30 interaction are difficult to discern. One 
important role of the CD30L-CD30 system is inhibition of function and apoptosis induction 
in certain situations [307,241]. CD30 has been found on activated T, B and NK cells, as well 
as in tumors of the immune system and in some nonhematolymphoid neoplasms [252]. 
Expression of the receptor is transient and certain effects appear to be opposed. CD30 
engagement is costimulatory for the growth and differentiation of specific T cells [308,309]. 
CD30L has been found on macrophages [241], B and T cells [310,242], eosinophils [311], 
erythrocyte precursors [312], leukemias cells [313] and mast cells [314]. CD30L stimulate the 
expression of both CD30 and IL-4 by T cells [315]. In this study, MCs were the predominant 
cell type expressing CD30L and the percentage of CD30L-positive MCs was significantly 
increased in the upper dermis of the BCC lesion, in agreement with a previous finding in 
psoriasis and atopic dermatitis [299]. In addition, even though the patient groups are not 
directly comparable in these studies, the percentage of CD30L-positive MCs in the healthy-
looking skin of BCC patients was similar to the situation in the healthy-looking skin of 
atopic dermatitis patients, but higher than in the healthy-looking psoriatic skin [52]. 
Furthermore, the colocation of CD30-positive cells with MCs in the upper dermis provides 
morphological evidence for the interaction between these cells. In addition, the interaction 
of soluble CD30 with MCs can activate them by reverse signaling and stimulate for 
increased secretion of proinflammatory IL-8 and TNF-α [257,252,52]. Furthermore, this 
interaction may explain the increased IL-8 expression in MCs in the BCC lesion. In clear 
contrast to the situation in the upper dermis, but in agreement with the previous reports 
[316], only few occasional cells of the BCC specimens showed CD30-immunopositivity in 
the epithelium but these cells represent other cells than BCC cells. Thus, the findings on 
CD30L and CD30 in BCC are not disease-specific and may be related to chronic 
inflammation, like in the case of psoriasis and atopic dermatitis. 
 
The CD40L-CD40 interaction regulates apoptosis positively or negatively, and may have 
some remarkable antitumor effects [317,318,319,320]. Data on CD40L expression on skin 
MCs is very limited. Previously it has been found that the BCC lesion does not show CD40L 
expression [321]. In agreement with these studies we found that skin MCs were devoid of 
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CD40L in both healthy-looking skin and BCC lesion. Thus, it is possible that skin MCs have 
lost their ability to express CD40L. However, the specificity of this finding needs to be 
clarified in other chronic inflammatory conditions of the skin, e.g. in psoriasis, atopic 
dermatitis and SCC. 
 
Similarly to previous reports [322,321], the CD40 receptor was localized to basal layer of the 
epidermis in healthy-looking skin. The situation was similar in superficial spreading BCC, 
where the basal layer showed positivity for CD40 receptor. However, it was confirmed like 
in the previous studies [322,321] that BCC cells, when protruding into the dermis forming 
basal buds and nests, loose their capability of expressing marked CD40. A similar situation 
was observed also for TNFRI, which showed faint immunopositivity in the larger basal 
buds. As a result, without the CD40L-CD40 system and TNFRI, BCC cells may be free to 
grow and invade into the dermis. Furthermore, it was also confirmed like in previous 
reports that the CD40-positive cells in the BCC dermis can be dendritic cells, endothelial 
cells and lymphocytes [322,321]. As the counterpart ligand CD40L is missing, the role of 
these cells in dermis is still obscure. 
 
MCs are the only cells expressing Kit receptor in the healthy and inflamed dermal skin 
[106,323]. As an almost equal number of cells positive to Kit and tryptase in the dermis of 
the healthy-looking skin and BCC lesion was found it can be concluded that all MCs 
express Kit receptor. Thus, the SCF-Kit system can act in the BCC lesion as BCC cells and 
peritumoral cells have previously been reported to express SCF [292]. 
 
6.3 TNF-α AND HISTAMINE HAVE A SIGNIFICANT GROWTH-
INHIBITORY AND CYTOLYTIC EFFECT ON NORMAL KERATINOCYTES BUT 
NOT ON CERVIX CARCINOMA CELL LINES SIHA AND ME-180 
 
Histamine together with TNF-α can induce a range of different effects on cells. Previously, 
histamine has been shown to inhibit the mitosis of keratinocytes [324]. When acting in 
conjuction on normal keratinocytes, histamine and TNF-α have shown synergism in the 
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induction of ICAM-1, probably through histamine H2-receptors [325]. In addition, ICAM-1 
expression in keratinocytes is known to lead to T cell activation and to increased lysis of 
keratinocytes by cytotoxic T cells [326]. In contrast, histamine may transiently also inhibit 
the actions of TNF-α on cells [327]. In peripheral blood mononuclear cells it can suppress 
gene expression and synthesis of TNF-α, again an effect mediated by H2-receptors [328]. In 
the present study, histamine or TNF-α alone induced growth inhibition of keratinocytes in 
a non-cytolytic manner. Furthermore, when histamine and TNF-α acted together, an 
increased growth inhibitory and cytolytic effect on normal keratinocytes was observed. 
Histamine and TNF-α in combination may activate and thereby induce ICAM-1 in 
keratinocytes and presumably have also other effects. Thus, preactivation of keratinocytes 
by histamine renders the cells more susceptible to the subsequent cytotoxic effects by TNF-
α or vice versa. Nevertheless, it is possible that there are still some unknown ways for the 
tissue to control the growth of the epidermis or epithelium. Since heparin binds efficiently 
TNF-α and augments the growth inhibition of keratinocytes induced by TNF-α [109], the 
combination of histamine, heparin and TNF-α may be even more potent for causing 
keratinocyte cytolysis. 
 
TNF-α can cause cytolysis to some cancer cell lines or, oppositely, it may stimulate cancer 
cell growth [329,330]. In cervical carcinomas caused by HPV viruses, TNF-α treatment 
seemed rather to maintain the growth, or even stimulate cell growth in one study, rather 
than cause growth inhibition and cytolysis of cervical carcinoma cells [331,332,333,291]. 
Furthermore, additional stressors such as protein synthesis inhibition or radiation are 
needed to induce cytolysis in these carcinoma cells by TNF-α [291,334]. Moreover, EGF has 
been found to be protective in ME180S cells, a cervical carcinoma cell line sensitive to TNF-
α, in TNF-α induced apoptosis [335]. In this study, TNF-α alone inhibited only slightly the 
growth of SiHa cells in a non-cytolytic manner, an inhibition, which was probably 
attributed to the slight growth arrest at G0/G1 phase of the cell cycle found in the serum-
free medium. 
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Previously, significantly decreased chemotactic migration of SiHa and CaSki cervical 
carcinoma cell lines to laminin-1 by TNF-α has been shown, while migration towards type I 
collagen was increased [336]. Moreover, TNF-α has a stimulatory effect on the migration of 
SW756 cervical carcinoma cells [337]. Thus, the present finding that TNF-α increased SiHa 
cell migration towards serum is in line with these previous findings. The weak growth 
inhibitory effect and the slight cell cycle arrest at the G0/G1 of SiHa cells evoked by TNF-α 
were associated with increased TNF-α induced SiHa cell migration. Thus, even though 
carcinoma cell proliferation is slightly inhibited, the better motility of these cells induced by 
TNF-α may enhance the spread of the tumor. 
 
Histamine has been proposed to be involved in the regulation of cancer growth as MCs can 
be found in increased numbers in the vicinity of tumors. In SCC cell lines HeLa and A431 
histamine has been found to stimulate the growth and chemotactic migration through the 
H1 receptor [338]. Moreover, histamine inhibited the production of interferon-induced 
protein of 10 kDa in the SCC15 SCC cell line via the H2 receptor [339]. Even though we 
confirmed the previous findings that histamine could inhibit the growth of monolayer 
proliferating keratinocytes as well as the growth of keratinocyte epithelium [340], histamine 
was not capable of influencing the growth, viability, cell cycle, migration and invasion of 
SiHa SCC cells. 
 
Emetine-sensitized SiHa cells have been shown to undergo cytolysis after treatment with 
TNF-α [291,341,342]. Nevertheless, the combination of histamine and TNF-α did not evoke 
any increased cytolysis effect in the SiHa cells pretreated with emetine. Similarly to the 
situation in SiHa cells, ME-180 cells were not markedly affected by the combined action of 
TNF-α and histamine suggesting that this may be a characteristic feature of SCC cells from 
different origins. 
 
TNFRI and TNFRII mediate the effect of TNF-α on the cell. In this study, these receptors 
were markedly expressed in normal keratinocytes but, in contrast, SiHa and ME-180 cells 
displayed weak immunoreactivity and only a few occasional cells appeared to clearly 
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display these receptors. This clear difference may provide one explanation why normal 
keratinocytes react to TNF-α and histamine in a cytolytic fashion but SiHa and ME-180 cells 
do not respond. Previously, immunoreactivity of TNF-α and TNFRI and II has been 
detected in tumor cells of SCC from head and neck as well as from the oral cavity [343,344]. 
Moreover, SiHa cells have been shown to express TNF mRNA [345]. Since SiHa cells 
displayed only weak TNFRI and II immunoreactivity in this study, TNF-α and TNFRs were 
stained also in cervical carcinoma specimens. Only one cervix carcinoma specimen out of 8 
revealed marked TNFRI or TNFRII immunopositivity and the same sample showed also 
high positivity for TNF-α. Large areas among tumor cell sites did not show staining for 
these receptors. Control samples showed higher scores of TNF-α and TNFRI or TNFRII. 
Thus, cervix carcinoma cells appear to contain lower levels of TNFRI and TNFRII when 
compared to the epithelium in samples with non-specific inflammation. Even though TNF-
α is expressed in cervix carcinoma, the tumor cells may not respond adequately due to lack 
of receptors. 
 
6.4 IS MC CHYMASE ABLE TO RELEASE SCC CELLS FROM TUMOR 
LEADING TO SPREADING OF MALIGNANT CELLS?  
 
Tryptase and chymase have been associated with a variety of human cancers [228;13]. 
Previously, it has been reported that there are increased numbers of MCs in the uterine 
cervical carcinoma and they were found to be predominantly of the MCT type [228]. 
However, the enzyme-histochemical technique on formalin-fixed and paraffin-embedded 
sections may not detect all chymase due to chymase inactivation during rough processing 
conditions. In the present study, the ratio of the number of chymase-positive cells to that of 
tryptase-positive cells was about 75-79 % in SCC specimens and about 74 % in control 
specimens suggesting that about 21-25 % of the MCs were of the MCT type in the SCC 
lesions. This percentage is much lower than the 80-83 % percentage of MCT cells described 
previously [228]. Thus, the present results clearly show the presence of chymase in cervix 
carcinoma, when chymase is stained with a mouse monoclonal antibody suitable for 
formalin-fixed and paraffin-embedded specimens. However, the use of formalin-fixed and 
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paraffin-embedded specimens in this work does not allow studying the activity level of 
chymase in a similar fashion as it was analyzed on cryosections from BCC samples (I). 
 
SCCA-2, α1-PI, α1-AC and SLPI are effective inhibitors of chymase [281], whereas no 
endogenous inhibitors are known for tetrameric tryptase and almost all tryptase-
immunopositive cells exhibit tryptase enzyme activity in cancer tissues [13]. Even though 
there is high structural homology between SCCA-2 and SCCA-1, there are differences in 
their capacity to inhibit proteinases: SCCA-1 inhibits cysteine proteinases and SCCA-2 
inhibits chymotryptic serine proteinases [281]. SCCA-2, which is secreted by SCC cells, may 
control the activity of chymase in the microenvironment between SCC cells and 
peritumoral MCTC MCs. Interestingly, clear differences were found in SCCA-1 and SCCA-2 
expression between SCC specimens and control specimens. The epithelium of control 
specimens with non-specific inflammation was immunonegative for SCCA-2, but positive 
for SCCA-1. In contrast, all SCC specimens were apparently immunonegative for SCCA-1. 
One SCC specimen out of 9 showed significant SCCA-2 immunoreactivity, 4 specimens 
revealed a few foci with some positive cells, and 4 specimens were negative. Thus, the 
expression of SCCA-2 immunoreactivity was higher in SCC specimens than in control 
specimens. However, the present finding of SCCA-2 and SCCA-1 expression in cervical 
SCC and control specimens is in agreement with studies showing increased ratio of SCCA-2 
mRNA to SCCA-1 mRNA in SCC in different tissues, including the uterine cervix [346;284]. 
 
Since MCTC cells were found to be predominant in SCC specimens and SCCA-2 expression 
was unexpectedly low rather than high, it was decided to examine whether the partially 
purified tryptase-chymase preparation from human skin [108] could influence the growth 
and adherence of cervical carcinoma cells in vitro using a well characterized SiHa cervical 
carcinoma cell line. Furthermore, in order to clarify which enzyme is responsible for the 
effects, specific inhibitors were used to block either chymase and/or tryptase. As a result, 
prolonged treatment with the tryptase-chymase preparation was found to induce the 
detachment of viable SiHa cells from the plastic surface and these cells continued their 
growth in an apparently normal fashion. Furthermore, the pretreatment of the fibronectin 
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coat with the tryptase-chymase preparation also resulted in reduced SiHa cell adherence 
onto the fibronectin coat. The experiments with inhibitors strongly suggest that it is 
chymase that induced SiHa cell detachment from substratum and one target of chymase is 
fibronectin that was degraded by rh-chymase. Similar results of the crucial role of chymase 
have previously been obtained with normal keratinocytes [108]. In fact, MC chymase has 
also been found to induce epidermis-dermis separation at the level of lamina lucida in skin 
biopsies in ex vivo experiments [163] and to cleave fibronectin, resulting in apoptosis in 
conjunctival epithelial cells [347] and smooth muscle cells [159]. Tryptase can also degrade 
fibronectin and induce focal epidermis-dermis separation in skin biopsies ex vivo [147]. 
However, the four active centers of a ring-like tetrameric tryptase are buried inside the 
protein facing a central pore [138] and as a result they may not reach pericellular matrix 
structures as efficiently as chymase [108]. Both enzymes are able also to activate latent 
metalloproteinases which may further increase cell detachment. Tryptase may also have a 
role in tumor growth by activating the protease-activated receptor-2 on tumor cells 
[348;349]. 
 
In this study, the prolonged treatment with rh-chymase detached viable and growing SiHa 
and ME-180 cells from the substratum but in contrast, in these conditions normal 
keratinocytes undergo apoptosis, similar to the effects found previously in conjunctival 
epithelial cells [347] and smooth muscle cells [159], probably due to a specific form of 
apoptosis, anoikis. Previously, it has been found that chymase can inhibit in a dose-
dependent manner the growth and migration of keratinocyte epithelium and monolayer 
keratinocytes [108] and it also inhibits the migration of monolayer conjunctival epithelial 
cells [350]. In this study, rh-chymase inhibited SiHa cell migration in a dose-dependent 
manner under the experimental conditions used. Since chymase pretreatment reduced the 
adherence of SiHa cells onto the fibronectin-coated plastic surface, it is possible that 
chymase interfered with cellular attachment process during migration or, alternatively, 
chymase at high concentration simply prevented SiHa cell adherence onto the porous 
transwell membrane. Previously, chymase has been found to release the hyaluronan 
receptor CD44 from cells, an effect which may modulate cell adherence [351].  
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Chymase-heparin proteoglycan complexes within MC granules are larger in size than 
tryptase-heparin proteoglycan complexes [352]. Thus, chymase tends to remain at the site 
of MC when compared to solubilization of tryptase [34,35]. As a result, chymase-heparin 
proteoglycan complexes may not diffuse efficiently to surround the cancer cell as is the case 
in the cell culture well. In addition, heparin may cause steric hindrance and thereby 
regulate the effects of chymase on carcinoma cells. However, chymase may be able to 
detach viable single carcinoma cells or cell groups from the tumor, and they can continue 
their growth as they migrate to more distant sites. On the other hand, in normal tissue, the 
detachment of normal keratinocytes by chymase led to decreased viability and increased 
apoptosis and thus it is possible that chymase attempts to control an excessive growth of 
epidermis and epithelium. In the same fashion, MCTC MCs and chymase may also strive to 
prevent the overgrowth of malignant epithelium by cleaving it off but ultimately they fail 
in this task. 
 
In previous studies, SiHa cells have been found to express SCCA-2 and its reduced 
expression is associated with increased migration and invasion of these cells and decreased 
E-cadherin expression [353,354]. Since chymase detached SiHa cells and inhibited their 
migration, it was studied whether these cells were able to modulate the activity of chymase. 
However, the sonicates of SiHa cells had no marked effect on chymase activity and only a 
tiny proportion of these cells exhibited marked immunoreactivity towards SCCA-1 and 
SCCA-2. Thus, even though SCCAs are expressed to some extent in SiHa cells, the amount 
of active SCCA-2 protein is not enough to control chymase activity in culture. Nevertheless, 
there is some discrepancy with the expression of SCCA-2, since its reduced expression in 
cervical SCC cells in vitro has been correlated with increased migration and invasion 
[353,354], but in contrast, an increased ratio of SCCA-2 mRNA to SCCA-1 mRNA in vivo is 
related with poorer prognosis of cervical SCC [346]. 
 
Taken together, the findings raise the possibility that mast cells could participate in cancer 
progression by affecting the growth, function, spreading and death of tumoral cells. 
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However, the role of other inflammatory cells and mediators in the process of cancer 
evolution should not be underscored. Future experiments will be necessary to determine 
the importance of the individual types of inflammatory cells in the onset, progression and 
execution of the pathological processes ultimately culminating in the cancer progression. 
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7 Conclusions 
 
1. Significant changes in MCs take place in the superficial spreading BCC: MCTC cells 
increase in number, but at the same time MCs contain increased levels of powerful chymase 
inhibitors α1-PI and α1-AC. Tryptase remains active but chymase is partially inactivated and 
therefore it may not be able to cleave the malignant epithelium away. However, residual 
chymase activity may still have the power to affect the basement membrane zone and 
SCCA-2 negative basal part and basal buds of the malignant epithelium. These changes in 
mast cells, however, appear not to be specific to this BCC type, and they rather reflect 
chronic inflammation. 
 
2. The number of MCs is increased in the BCC lesion, possibly as a result of SCF-Kit 
activation. In addition, MCs are increasingly immunopositive for CD30L and possibly for 
TNF-α, but are almost negative for CD40L, in the BCC lesion. This suggests selective 
expression and up-regulation of certain TNF superfamily ligands in MCs. An increase in 
the number of positive cells for the receptors of CD30L and TNF-α in the upper dermis of 
the BCC lesion suggests that MC CD30L and TNF-α may affect and modulate the dermal 
immune system. In addition, the decrease of chymase activity may allow enhanced MC 
TNF-α effects on dermal immune cells. The lack of CD40L in MCs and the lack of CD40 and 
TNFRI in basal buds can be of importance for the inefficient antitumoral response in BCC. 
However, the changes in MC CD30L and TNF-α are not disease-specific to BCC. 
 
3. The combination of TNF-α and histamine has a profound growth-inhibitory and cytolytic 
effect on normal keratinocytes but, in contrast, this combination showed no significant 
effect on the growth, viability, cell cycle, migration and invasion of SiHa cells suggesting 
that these cells have lost their capability of reacting to this endogenous cytolytic 
mechanism, possibly due to their lower TNFRI and TNFRII expression. Similarly, another 
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SCC cell line, ME-180, was also resistant to the combined action of TNF-α and histamine. 
TNF-α alone induced only slight growth inhibition and cell cycle arrest at the G0/G1 phase 
in serum-free medium but was capable of increasing the migration of SiHa cells. Since TNF-
α was found in the cervix carcinoma tissue, it may promote the spread of carcinoma cells. 
Furthermore, the expression level of TNFRI and TNFRII in the tumor cells of cervix 
carcinoma may not be sufficient to evoke the cytolytic changes normally induced by TNF-α. 
 
4. Significant numbers of MCTC cells are present in the peritumoral stroma of uterine 
cervical SCC. A higher SCCA-2 expression was found in cervical SCC specimens than in 
control specimens, though only one out of nine SCC specimens showed marked SCCA-2 
immunoreactivity. When compared to the effect of tryptase in the tryptase-chymase 
preparation, it appears that it is chymase that is capable of detaching viable and growing 
SiHa and ME-180 SCC cells and therefore chymase may be able to release single SCC cells 
or cell groups from a tumor leading to the spread of malignant cells. 
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The possible role of MC mediators 
was investigated in SCC and BCC 
carcinomas. Novel information on 
the MC proteinases tryptase and 
chymase in SCC and BCC carcinomas 
is presented and their potential to 
degrade the extracellular matrix is 
discussed. Moreover, the presence 
MCs cytokines and their counter-
part receptors is also described. The 
results demonstrate that chymase 
may release viable tumoral cells 
that tolerate the cytolytic action of 
TNF-α and histamine leading to the 
spread of SCC. In BCC, MCs express 
TNF-α and CD30 ligand but the lack 
of CD40L may be responsible of the 
inefficient antitumoral response.
